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Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive diffuse parenchymal 
lung disease of unknown etiology (Ley et al., 2011). Existing evidence strongly 
suggests that the alveolar epithelial cell (AEC) is the key player in the pathogenesis of 
IPF. It is believed that repetitive cycles of epithelial cell injury, followed by impaired 
wound healing, lead to an excessive apoptosis of AECs, accompanied by aberrant 
activation of fibroblasts/myofibroblasts, deregulated remodeling and, finally, 
irreversible restructuring of the lung parenchyma (Selman et al., 2002, Zoz et al., 2001).  
Hepatocyte growth factor (HGF) is a pleiotropic cytokine playing a major role in 
cellular repair processes, ensuring restoration of epithelial homeostasis in the damaged 
organ. Exogenous administration of HGF has been reported beneficial in experimental 
models of various organ fibrosis including the lung. Bcl-xL is an anti-apoptotic member 
of Bcl-2 family which consists of highly conserved proteins involved in the 
mitochondrial control of apoptosis. Since HGF signaling via c-Met receptor has been 
proposed to regulate the expression of Bcl-2 family members, the present study was 
performed to evaluate the potential role of Bcl-xL in HGF-mediated epithelial 
protection in IPF. We therefore aimed to characterize Bcl-xL expression and its cellular 
localization in lung tissues of IPF patients in comparison to donor lung tissues, to 
investigate if HGF mediates pro-survival effects on alveolar epithelial cells regardless 
of the kind of pro—apoptotic stimulus and to assess the potential role of Bcl-xL in this 
context.  
Employing tissues from human IPF and donor lung resections, we observed that Bcl-xL 
protein was highly expressed in hyperplastic AECII found in regions of dense fibrosis in 
IPF. Donor lung tissues revealed a much weaker signal for Bcl-xL in the alveolar 
epithelium. These findings were confirmed by Western blot analysis which revealed a 
significant increase in the total Bcl-xL amount in IPF lung versus donor lung 
homogenates. Furthermore, staining for Bcl-xL in AECII in still regular imposing areas 
was less prominent than in hyperplastic AECII present in fibroblastic regions. 
In vitro studies were performed on mouse (MLE12, MLE15) and rat (RLE-6TN) 
alveolar epithelial cell lines. Since it has been reported that human IPF is characterized 
by permanent oxidative stress, enhanced activation of ER stress and up-regulation of 
Fas ligand (FasL), we chose hydrogen peroxide, thapsigargin and FasL as apoptosis-
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inducing factors in this study. We observed that simultaneous treatment with HGF and 
hydrogen peroxide or thapsigargin resulted in an improved survival of alveolar 
epithelial cells. In both cases, the HGF-mediated anti-apoptotic activity was associated 
with increased Bcl-xL expression and the beneficial effect of HGF could be abolished 
by using a c-Met specific inhibitor prior to HGF incubation. The siRNA-mediated 
knock-down of Bcl-xL caused an increased susceptibility of the epithelial cells to 
injury. However, although less efficient, HGF treatment still remained profitable and 
resulted in improved cell survival despite of the low level of Bcl-xL. Interestingly, 
FasL-triggered activation of Caspase 3 did not affect the expression level of Bcl-xL. In 
line with these results, we did not observe a beneficial effect of HGF on FasL-induced 
apoptotic cells.  
Altogether, our findings demonstrate that i) Bcl-xL is up-regulated in human IPF, 
predominantly in AECII and especially in areas with dense fibrosis, ii) knock down of 
Bcl-xL makes alveolar epithelial cells much more susceptible to injury and cell death, 
iii) Bcl-xL accounts at least in part for the HGF-elicited epithelial protection against 
oxidative as well as ER stress. Bcl-xL therefore offers as interesting candidate for 
epithelial-protective therapies in IPF and other forms of lung fibrosis associated with 
epithelial apoptosis. 
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Die Idiopathische Pulmonale Fibrose (IPF) ist eine chronische, progressiv verlaufende 
Diffus Parenchymatöse Lungenerkrankung (DPLD), deren Ursache noch nicht 
vollständig bekannt ist (Ley et al., 2011). Es gibt vermehrte Hinweise, dass 
Alveolarepithel Typ II Zellen (AECII) eine zentrale Rolle bei der Pathogenese der IPF 
spielen. Man nimmt an, dass repetitive Schädigungen epithelialer Zellen, gefolgt von 
einer abnormalen Wundheilungsreaktion zu einer exzessiven Apoptose der AECII 
führen, die zusammen mit der Aktivierung von Fibroblasten/Myofibroblasten und 
einem dysregulierten Remodeling schließlich in einem irreversiblen Umbau des 
Lungenparenchyms münden (Selman et al., 2002, Zoz et al., 2001). Der 
Hepatozytenwachstumsfaktor (Hepatocyte Growth Factor, HGF) ist ein Zytokin mit 
pleiotropen Funktionen, der wesentlich für zelluläre Reparaturprozesse verantwortlich 
ist und in der Lage ist die epitheliale Homöostase in geschädigten Organen 
wiederherzustellen. Die exogene Verabreichung von HGF hat sich in 
tierexperimentellen Modellen verschiedener Organfibrosen, einschließlich der Lunge, 
als therapeutisch wirksam erwiesen. Bcl-xL ist ein anti-apoptotisch wirksamer Vertreter 
der Bcl-2 Familie, die aus hochkonservierten Proteinen besteht und an der 
mitochondrialen Kontrolle der Apoptose beteiligt ist. Da in früheren Studien gezeigt 
werden konnte, dass HGF über seinen Rezeptor cMet die Expression von Mitgliedern 
der Bcl-2 Proteinfamilie zu regulieren vermag, wurde in der vorliegenden Arbeit 
untersucht, inwieweit Bcl-xL an der HGF-vermittelten Protektion epithelialer Zellen bei 
der IPF beteiligt ist. Ziel war es die Bcl-xL Expression und deren zelluläre Lokalisation 
in IPF-Lungen im Vergleich zu gesunden Spenderlungen zu charakterisieren, und zu 
untersuchen, ob die HGF-vermittelten Epithelzell-protektiven Effekte unabhängig von 
der Art des apoptotischen Stimulus sind und welche Rolle Bcl-xL in diesem 
Zusammenhang spielt.  
Im Vergleich zu nicht utilisierten Donorlungen konnte im Lungengewebe von IPF 
Patienten eine signifikant erhöhte Expression des Bcl-xL Proteins, vor allem in 
hyperplastischen AECII und Bereichen mit dichter Fibrose, nachgewiesen werden. Bcl-
xL war ebenfalls in AECII von Donorlungengewebe nachweisbar, wurde dort allerdings 
deutlich schwächer exprimiert. Diese Befunde wurden durch Western Blot Analysen, 
die einen signifikanten Anstieg des Bcl-xL im Lungenhomogenat von IPF Lungen 
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versus Donorlungen zeigten, gestützt. In IPF Lungen war in Bereichen mit einer 
weitgehend normalen Lungenstruktur die immunhistochemische Anfärbung für Bcl-xL 
in AECII deutlich abgeschwächt, verglichen mit hyperplastische AECII in Bereichen 
mit einem starken Geweberemodeling. 
An Maus (MLE12, MLE15) und Ratten (RLE-6TN) Epithelzelllinien wurden in vitro 
Versuche durchgeführt. Da bei der Pathogenese der IPF oxidativer Stress, Induktion von 
ER-Stress und eine erhöhte Expression von Fas Ligand (FasL) beschrieben ist, wurden 
für die Zellkulturversuche Wasserstoffperoxid, Thapsigargin und FasL als Apoptose-
indizierende Stimuli eingesetzt. Eine gleichzeitige Behandlung der Zellen mit HGF und 
Wasserstoffperoxid bzw. HGF und Thapsigargin führte zu einer gesteigerten 
Überlebensrate der Zellen. In beiden Fällen war parallel zu den HGF-vermittelten anti-
apoptotischen Effekten ein Anstieg der Bcl-xL Expression zu beobachten. Der 
protektive HGF Effekt konnte durch unter Verwendung eines cMet-spezifischen 
Inhibitors aufgehoben werden. Der siRNA-vermittelte Knockdown von Bcl-xL führte zu 
einer erhöhten Empfindlichkeit der Epithelzellen gegenüber den schädigenden 
Agenzien. Eine gleichzeitige Behandlung der Zellen mit HGF erwies sich –wenn auch 
in geringerem Umfang- als zellprotektiv und führte trotz geringerer Bcl-xL Spiegel zu 
einer verbesserten Überlebensrate der Zellen. Interessanterweise hatte die FasL 
vermittelte Aktivierung von Caspase 3 keinen Einfluß auf die Bcl-xL Spiegel, und 
ebenso hatte HGF keinen protektiven Einfluss auf die FasL-induzierte Apoptose von 
Epithelzellen.  
Zusammenfassend zeigen unsere Ergebnisse, dass i) Bcl-xL bei der IPF erhöht ist, 
vornehmlich in AECII und speziell in Bereichen mit starker Fibrosierungsreaktion, ii) 
der Knockdown von Bcl-xL Alveolarepithelzellen anfälliger gegenüber einer 
Schädigung und Apoptoseinduktion macht , iii) Bcl-xL zumindest teilweise für den 
HGF-vermittelten Schutz von Epithelzellen gegenüber oxidativem Stress und ER-Stress 
verantwortlich ist. Bcl-xL bietet sich somit als ein potentieller Kandidat für Epithelzell-
protektive Therapieregimen bei der IPF und anderen Formen von Lungenfibrose mit 
erhöhter epithelialer Apoptose an.  
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1 Introduction 
1.1 Idiopathic pulmonary fibrosis 
1.1.1 Epidemiology and clinical features of idiopathic pulmonary 
fibrosis 
 
Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown etiology, 
characterized by progressive and irreversible course. It is the most common and severe 
form of idiopathic interstitial pneumonia (IIP), a group of entities that belongs to the 
diffuse parenchymal lung diseases (Meltzer et al., 2008). IPF is a relatively rare 
condition and has a poor prognosis, with a median survival of 2,5 to 3,5 years from the 
time of diagnosis (Ley et al., 2011). The annual incidence fluctuates between 4,6 and 
16,3 cases per 100000 and the prevalence is estimated to be 2 to 29 cases per 100000 
people in general population, with higher frequency in men than women (Raghu et al., 
2011). While some patients show a stable progression rate of the disease for extended 
time periods, the individual outcome is highly variable, as acute exacerbations may 
occur in an unpredictable manner (Meltzer et al., 2008). 
Patients with IPF typically suffer from dry, non-productive cough and dyspnea upon 
excercise, which progresses into breathlessness at rest (White et al., 2003). On chest 
examination, inspiratory Velcro-like crackles can be auscultated in basilar lung regions. 
In up to half of all patients, finger clubbing is observed. In general, manifestation of IPF 
occurs in middle-aged and elderly adults, with a mean age at presentation of 66 years 
(King et al., 2011).  
Due to the lack of specific symptoms, the clinical diagnosis of IPF requires an 
integrated approach. First of all, radiological and/or histological pattern characteristic 
for “usual interstitial pneumonia” (UIP) has to be evident and other forms of IIP caused 
by known factors, such as an environmental exposure to an inhalable irritant 
(e.g. asbestos), systemic disease (e.g. collagen vascular disease) or drug treatment 
(e.g. amiodaron), have to be excluded (Raghu et al., 2011). Secondly, restriction on 
pulmonary function should be observed, including reduced total lung capacity, 
decreased values of forced vital capacity (FVC) and forced expiratory volume in one 
second (FEV1) alongside with impaired gas exchange (Martinez et al., 2006). 
In principle, the disease is highly heterogeneous concerning its phenotype as well as the 
clinical course. The complexity of IPF still remains a challenge and only limited 
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treatment options are available. Only recently, next to the lung transplantation (Chan et 
al., 2013), pirfenidone has become available as anti-fibrotic treatment in Europe (Cottin, 
2013). Given that, considerable progress towards the understanding and treatment of 
this devastating disease should be made within the next years. 
 
1.1.2 Histopathology of idiopathic pulmonary fibrosis 
 
Idiopathic pulmonary fibrosis is associated with the histological pattern known as usual 
interstitial pneumonia (UIP). The key features of UIP comprise spatial heterogeneity, 
alveolar septal thickening, peripheral fibrosis with mild inflammation, presence of 
fibroblastic foci and microscopic honeycomb changes (Figure 1.1).  
 
 
 
Figure 1.1: Histopathological features of usual interstitial pneumonia. 
Characteristics of advanced fibrosis in usual interstitial pneumonia of idiopathic pulmonary fibrosis 
include (A) a subpleural distribution of fibrosis, 20x, (B) relative frequency of fibroblast foci (arrows) 
and relative absence of inflammatory cell infiltrate, 400x, (C) smooth muscle proliferation in the 
subpleural scars (asterisk), 40x, (adapted from Smith et al., 2013).  
 
Heterogeneity is the most striking feature of UIP. In biopsies obtained from patients 
with IPF, regions with normal lung architecture alternate with patchy areas of 
histologically apparent parenchymal fibrosis (Meltzer et al., 2008). At the border 
between normal appearing and within the scar regions, a variable number of clusters of 
fibroblast/myofibroblast, termed fibroblastic foci, are found. They are believed to 
represent the active lesions of UIP (White et al., 2003). In those active regions, alveolar 
epithelial injury with hyperplastic alveolar epithelial type II cells (AECII) and alveolar 
septal thickening is often seen (King et al., 2011). Adjacent to pleural surface, enlarged 
cystic airspaces, termed honeycombing can be observed (White et al., 2003). The 
inflammation is mild and mostly associated with areas of collagen deposition or 
honeycombing. It seldom affects unaltered alveolar septa (Selman et al., 2001). In 
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patients with smoking history, additionally emphysema or respiratory bronchitis can 
occur next to the UIP pattern (Meltzer et al., 2008). 
 
1.1.3 Pathogenesis of idiopathic pulmonary fibrosis 
 
IPF is a chronic, progressive and irreversible disease of unknown origin. Despite 
extensive research, the mechanisms underlying the evolution of the disease remain 
poorly understood. According to a current concept, repetitive injury to alveolar 
epithelial cells (AECs) with consecutive aberrant wound healing process and disturbed 
crosstalk between epithelial cells and fibroblasts is thought to be the driving force for 
the development of pulmonary fibrosis (Jenkins et al., 2012). Indeed, a growing number 
of publications in the field suggests, that apoptosis of AEC may be the leading cause of 
the disease progression. Activation of oxidative and ER stress response pathways, 
telomere shortening and genetic factors such as surfactant protein C or other mutations 
and alterations in the cellular microenvironment maintained by activated myofibroblasts 
perpetually increase the susceptibility of alveolar type II cells to apoptosis (Jin et al., 
2011; Hecker et al., 2011) (Figure 1.2). 
In IPF, a severe imbalance between oxidants and antioxidants has been observed. 
Analysis of the epithelial lining fluid from IPF lungs showed increased levels of 
hydrogen peroxide, lipid oxidation products and oxidized proteins with carbonyl 
modifications. In contrast, there is a reduced antioxidant protection, for example 
decreased levels of glutathion in bronchoalveolar lavage fluid (BALF) and superoxide 
dismutase, especially in fibrotic regions of UIP lungs (Kliment et al., 2010). Excessive 
production of reactive oxygen species (ROS) may contribute to IPF pathogenesis via 
various pathways, such as altered cytokine expression, induction of apoptosis of 
epithelial and endothelial cells or activation of fibroblast (Waghray et al., 2005, Walters 
et al., 2008). 
Another factor that may contribute to the development of pulmonary fibrosis is a 
genetic predisposition. Telomerase activity is crucial for the proliferation and proper 
repair of alveolar epithelial cells. Loss of function mutations in telomerase components 
has been observed in 8-15% of familial IPF cases (Armanios et al., 2007). Telomere 
shortening in various cell types, like type II cells or circulating leukocytes, has been 
described in patients with sporadic, familial and idiopathic pulmonary fibrosis (King et 
Introduction 
4 
al., 2011, Zoz et al., 2011). Telomere shortening leads to loss of AECII during re-
epithalisation of injured alveoli, which in turn drives a fibrotic response (Whitsett et al. 
2010). Moreover, genetic mutations in surfactant protein C (SP-C) and A (SP-A) have 
been linked to familial cases of IPF (Kropski et al., 2013). Accumulation of misfolded 
SP-C can lead to activation of the unfolded protein response (UPR) and ER 
(endoplasmic reticulum) stress induction (Korfei et al., 2008). Since SP-C is exclusively 
expressed by type II cells in the lung, the described mechanism may directly affect and 
promote AECII apoptosis, potentially leading to the progression of fibrotic process (Jin 
et al., 2011). 
 
 
 
Figure 1.2: Hypothetical scheme for IPF pathogenesis (adapted from Zoz et al., 2011). 
 
Apart from determining the etiology of the primary injury that triggers development of 
IPF, the mechanisms responsible for the progressive nature of fibrotic process, even 
without presence of the initial stimuli, need to be elucidated. Sustained deregulation of 
epithelial-fibroblast crosstalk, with constant deterioration of alveolar epithelial cells and 
expansion of activated fibroblasts/myofibroblasts, with excessive deposition of 
extracellular matrix, might contribute to pathogenesis of IPF (Selman et al., 2002). 
Strong evidence indicates that AECII are the primary source of chemotactic factors and 
mitogens for mesenchymal cells, e.g. platelet-derived growth factor (PDGF), 
transforming growth factor β (TGF-β) or tumor necrosis factor α (TNF-α). That in turn 
Ongoing, repetitve exposure to noxious environmental stimuli 
Dysfunctional type II AEC phenotype 
(genetic or aquired) 
Increased AEC injury/apoptosis 
Abnormal repair 
(fibroblast recruitment, activation) 
Fibrosis 
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promotes the expansion of fibroblasts, their trans-differentiation into α-smooth muscle 
actin-positive myofibroblasts and reinforce maintenance of a fibrotic phenotype 
characterized by high mechanical stress, local further increase of TGF-β synthesis or 
presence of specialized matrix proteins, like ED-A fibronectin (King et al., 2011). 
Additionally, TGF-β has also a negative effect on alveolar epithelial cells, for example 
via enhancing the Fas-mediated apoptosis of these cells (Hagimoto et al., 2001) 
(Figure 1.3). 
 
 
 
Figure 1.3: Overview of key pathogenic mechanisms in IPF. 
Following unidentified insult, alveolar epithelial cells become injured and delayed re-epithelialization 
leads to a denuded, disrupted basement membrane. A ﬁbrin clot forms early and serves as a provisional 
matrix for the migration and proliferation of reparative alveolar epithelial cells. Neutrophils secrete pro-
inﬂammatory mediators, reactive oxygen species and MMPs, while recruited lymphocytes elaborate the 
Th2-type cytokines. Fibroblasts migrate into the wound and produce extracellular matrix proteins and 
mediators such as Angiotensin II which may further promote alveolar epithelial cell apoptosis. Alveolar 
macrophages and epithelial cells secrete TGF-β1, which promotes myoﬁbroblast differentiation, increases 
extracellular matrix production, and inhibits apoptosis of ﬁbroblasts/myoﬁbroblasts. Reciprocal 
communication between alveolar epithelial cells and mesenchymal cells results in a positive feedback 
loop that promotes ongoing ﬁbrosis and destruction of alveolar architecture (adapted from 
White et al., 2003). 
 
Despite the fact, that many elements of the innate and adaptive immune response 
participate in the differentiation and activation of fibroblasts (Wynn et al., 2012), it is 
still a controversial issue, if inflammation plays a significant role in the pathogenesis of 
IPF. In IPF lung tissue as well as in BAL fluid, some inflammatory cells known to 
produce various growth factors and cytokines exacerbating fibrosis can be found, 
including neutrophils, macrophages, plasma cells and lymphocytes. Based on the 
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evidence that inflammation itself is usually described as minimal to mild and combined 
immunosuppressive therapy with corticosteroids has been proven harmful to IPF 
patients (Jin et al., 2011, IPF Clinical Research Network et al., 2012), the current 
hypothesis postulates that inflammation is neither a triggering factor of IPF nor the 
major player in its pathogenesis (Bringardner et al., 2008) 
Since idiopathic pulmonary fibrosis is a complex disease, the mechanisms underlying 
its pathogenesis may involve a number of molecular pathways that result in loss of 
cellular homeostasis within the alveolar wall and expansion of mesenchymal cells in the 
interstitium.  
 
1.2 Hepatocyte growth factor 
1.2.1 HGF/c-Met signaling pathway 
 
Hepatocyte growth factor (HGF) is a pleiotropic cytokine playing major roles in the 
control of tissue homeostasis and regeneration, as well as during embryonic 
development. In mature organs, it promotes proliferation, survival, motility, 
differentiation and morphogenesis in diverse cell types. Besides, it is crucial for 
migration of skeletal muscle progenitor cells (Bladt et al., 1995) and essential for 
embryonic development of liver (Schmidt et al., 1995), placenta (Uehara et al., 1995), 
nervous system (Maina et al., 1999) and epithelial morphogenesis in different organs 
including the lung (Ohmichi et al., 1998). 
HGF is mainly produced by cells of mesenchymal origin and secreted as a single-chain 
precursor. Specifically at the site of injury, HGF is converted by proteolytic cleavage 
into its biologically active form. Several proteases in the serum or cell membrane are 
responsible for the activation process, including HGF activator (HGFA), urokinase-type 
plasminogen activator (uPA), coagulation factors XI and XII and matriptase. The 
cleavage occurs between Arg 494 and Val 495 residues. The mature form of HGF is a 
heparin-binding, heterodimeric glycoprotein composed of α and β subunit linked by a 
disulphide bond. The 69 kDa α subunit consists of N-terminal hairpin loop and four 
kringle domains, whereas β subunit is smaller (34 kDa) and has serine protease-like 
structure (Nakamura et al., 2010, Nakamura et al., 2011) (Figure 1.4 A). In the activated 
form, HGF is recognized by the specific cell surface receptor c-Met, expressed mainly 
in the epithelial cells of various organs, including the liver, kidney and lung. The mature 
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c-Met receptor is a heterodimeric protein composed of structural domains that include 
extracellular Sema, PSI and IPT domains, the transmembrane domain and the 
intracellular tyrosine kinase catalytic domain flanked by juxtamembrane and C-terminal 
sequences (Figure 1.4 B). 
 
 
 
Figure 1.4: Structural characteristics of HGF and c-Met. 
(A) HGF is secreted as a single-chain form and is converted into its biologically active form upon 
proteolytical cleavage between Arg and Val residues (green arrow). The mature form consists of α and β 
subunits linked by a disulphide bond. The α-chain contains N-terminal hairpin loop followed by four 
kringle domains (K 1-4). (B) c-Met receptor is a single-pass, disulphide linked heterodimer. The 
extracellular part is composed of three domain types: semaphorin domain (Sema), the plexin-semaphorin-
integrin (PSI) domain and immunoglobulin-plexin-transcritpion (IPT) domains. The c-Met receptor 
contains tyrosine catalytic domain flanked by juxtamembrane domain and the multifunctional docking 
site in the C-terminal tail. (Adapted from Nakamura et al., 2010, Organ and Tsao, 2011). 
 
 
Direct interaction between the receptor and HGF occurs via high affinity binding of the 
HGF α subunit to the extracellular portion of the receptor, and the low affinity binding 
of the HGF β subunit to c-Met Sema domain which is necessary for inducing signal 
transduction. HGF association leads to homodimerization of the receptor and 
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phosphorylation of two tyrosine residues (Tyr 1234 and Tyr 1235) located within its 
catalytic loop. Subsequently the C-terminal Tyr 1349 and Tyr 1356 become 
phosphorylated which results in the recruitment of intracellular signaling molecules that 
include adaptor proteins, e.g. growth factor receptor-bound protein 2 (Grb2), Grb2-
associated binder 1 (Gab1), SH2-containing protein tyrosine phosphatase 2 (Shp2) and 
the effector molecules, like phosphatidylinositol 3 kinase (PI3K), phospholipase C γ 
(PLCγ), signal transducer and activator of transcription 3 (STAT3) and the v-src 
sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (Src). A large range of adaptor 
molecules, among which some function as additional platform for binding another 
proteins (e.g. Gab1), is the key to c-Met-mediated wide variety of cellular responses 
(Figure 1.5). Furthermore, the specific downstream response to c-Met activation can be 
affected by phosphorylation of additional tyrosine residues (Tyr 1313 and Tyr 1365) or 
be negatively regulated by phosphorylation of serine 985 and tyrosine 1003 (Nakamura 
et al., 2011, Organ et al. 2011). As a consequence, HGF/c-Met signaling pathway is 
able to regulate many distinct cellular processes in a controlled, accurate and well 
orchestrated manner.  
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Figure 1.5: HGF-mediated c-Met signaling. 
HGF binding to c-Met results in receptor homodimerization and tyrosine phosphorylation with multiple 
downstream effects. Each biological activity is elicited through recruitment of specific adaptor proteins. 
(Adapted from Organ and Tsao, 2011) 
 
1.2.2 HGF as a fibrosis resolving factor 
 
Under normal conditions, induction of endogenous HGF production following tissue 
injury is principally sufficient for proper regeneration and wound healing process 
leading to restoration of homeostasis in the damaged organ. However, during 
development and progression of fibrosis, the intrinsic production of HGF appears to be 
insufficient to promote full recovery and reduction of fibrotic changes (Crestani et al., 
2012). Studies on animal models have provided strong evidence that supplementation of 
exogenous HGF has a beneficial role in a wide range of fibrotic disorders in various 
organs, including the lung, kidney, liver and heart (Table 1). In the rodent model of 
bleomycin-triggered pulmonary fibrosis, simultaneous or delayed administration of 
recombinant HGF protein or of HGF gene therapy, were both successful in ameliorating 
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fibrotic lesions, reducing the hydroxyproline content in the lung and improving survival 
rate of experimental animals. Administration of exogenous HGF has also been shown to 
restore kidney and liver function in corresponding models of liver cirrhosis and kidney 
fibrosis, suppress collagen deposition and finally resulting in resolution of fibrosis.  
 
Organ Model of disease 
(animal) 
HGF 
application 
(apporach) 
Outcomes References 
Heart Genetic model of 
cardiomyopathy 
(hamster) 
SC, rHGF 
(therapeutical) 
↓ cardiac fibrosis, 
↓ expression of TGF-β1 
and collagen I, ↑ cardiac 
function 
Nakamura et al., 
2005 
Liver DMN model of 
cirrhosis (rat) 
IV, rHGF 
(preventive) 
↑ ECM degrading 
enzymes, ↓ ECM 
components, ↑ survival 
rate 
Matsuda et al., 
1995 
Liver Bile duct ligation-
induced cirrhosis 
(mouse) 
IV, HGF cDNA 
(preventive) 
↓ fibrotic lesions, 
↓ α-SMA and TGF-β, 
↓ hydroxyproline content 
Xia et al., 2006 
Liver DMN model of 
cirrhosis (rat) 
IP, rHGF 
(preventive) 
↓  α-SMA, histological 
resolution of cirrhosis 
Kim et al., 2005 
Liver DMN model of 
cirrhosis (rat) 
IM, HVJ-HGF 
(therapeutical) 
↓ TGF-β, resolution of 
fibrosis, ↑ survival rate 
Ueki et al., 1999 
Lung Bleomycin model 
of fibrosis (mouse) 
IP, rHGF 
(preventive and 
therapeutical) 
↓ hydroxyproline content, 
↓ pulmonary fibrosis 
Yaekashiwa et al., 
1997 
Lung Bleomycin model 
of fibrosis (mouse) 
IT, rHGF 
(therapeutical) 
↓ hydroxyproline content, 
↓ fibrotic score 
Dohi et al., 2000 
Lung Bleomycin model 
of fibrosis (mouse) 
IM, HGF cDNA 
(preventive and 
therapeutical) 
↓ lung and dermal 
fibrosis, ↓ collagen 
content, ↓ TGF-β 
Wu et al., 2004 
Lung Bleomycin model 
of fibrosis (mouse) 
IM, HGF cDNA 
(preventive) 
↓ fibrotic score, 
↓ hydroxyproline content, 
↓ apoptosis of epithelial 
cells 
Umeda et al., 
2004 
Lung Bleomycin model 
of fibrosis (mouse) 
SC, rHGF 
(preventive) 
↓ hydroxyproline content, 
↑ MMP-1 and MMP-9, 
↑ myofibroblast apoptosis 
Mizuno et al., 
2005 
Lung Bleomycin model 
of fibrosis (mouse) 
IV, HGF cDNA 
(preventive and 
therapeutical) 
↑ IL-6 and TNF-α, 
↑ endogenous HGF 
expression, 
↓ hydroxyproline content, 
↑ survival rate 
Watanabe et al., 
2005 
Lung Bleomycin model 
of fibrosis (rat) 
IT, HGF cDNA 
(therapeutical) 
↓ fibrotic score, 
↓ hydroxyproline content, 
↓ TGF-β, ↓ apoptosis of 
epithelial cells 
Gazdhar et al., 
2007 
Lung Bleomycin model 
of fibrosis (rat) 
IM, HGF cDNA 
(preventive and 
therapeutical) 
↓ fibrotic score, 
↓ hydroxyproline content, 
↑ COX-2 
Long et al., 2007 
Kidney Spontaneous model 
of CRD (mouse) 
SC, rHGF 
(preventive) 
↑ tubular repair, ↑renal 
function, ↓ TGF-β and 
PDGF 
Mizuno et al., 
1998 
Kidney UUO-induced renal 
fibrosis (mouse) 
IV, rHGF 
(therapeutical) 
↓  fibrosis, ↓ collagen 
content, ↓ TGF-β and 
fibronectin 
Yang and Liu, 
2003 
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Kidney UUO-induced renal 
fibrosis (mouse) 
IV, HGF cDNA 
(preventive) 
↑ endogenous HGF 
expression, ↓ collagen I, 
↓  fibronectin, ↓ TGF-β, 
↓  α-SMA 
Yang et al., 2001 
 
Table 1: Effects of exogenous HGF administration in animal models of different organ fibrosis. 
CRD – chronic renal disease, DMN – dimethyl nitrosamine, ECM – extracellular matrix, HVJ-HGF – 
hemagglutinating-virus-of-Japan liposome containing HGF cDNA, rHGF – recombinant HGF, UUO – 
unilateral ureteral obstruction, IP – intraperitoneal, IM – intramuscular, IT – intratracheal, IV – 
intravenous, SC – subcutaneous, (modified from Crestani et al., 2012, Nakamura et al., 2010) 
 
The anti-fibrotic actions of HGF may be mediated via multiple direct and indirect 
mechanisms (Figure 1.6). As a regenerative factor, HGF is thought to block apoptosis 
and promote proliferation of epithelial and endothelial cells, thereby promoting injury-
initiated repair. Three predominant pathways have been implicated in HGF pro-survival 
and pro-mitogenic signaling: ERK/MAPK, PI3K/Akt and STAT3 (Panganiban 
and Day, 2011). Although HGF was shown to stimulate proliferation through the ERK-
STAT3 pathway and to have anti-apoptotic action through PI3K/Akt pathway in human 
aortic endothelial cells (Nakagami et al., 2001), not much is known up to date about its 
anti-apoptotic properties on alveolar epithelial cells. In analogy to other studies, it is 
assumed that it may occur through PI3K/Akt kinase signaling pathway. PI3K/Akt 
pathway has been reported to play a major role in HGF-mediated protection of 
hepatocytes (Moumen et al., 2007) and mouse lung endothelial cells (Wang et al., 
2004). However, the exact mechanism remains unknown. Moreover, HGF has been 
demonstrated to induce DNA synthesis in primary rat alveolar type II cells in vitro 
(Shiratori et al., 1995) and in vivo (Panos et al., 1996). 
Another important mechanism involved in HGF-driven resolution of fibrosis maybe the 
reduction of myofibroblast accumulation. In chronically injured organs, interstitial 
myofibroblasts are the major source of extracellular matrix deposition and the key 
mediators of pro-fibrotic remodeling that leads to distortion of normal tissue 
architecture (Wynn et al., 2012). In the lung, HGF has been identified to specifically 
elicit myofibroblast apoptosis via indirect mechanisms associated with increased 
activity of matrix metalloproteinases (MMPs), thus leading to the degradation of the 
ECM components (Mizuno et al., 2005). Additionally, HGF appears to be responsible 
for sustaining quiescent phenotype of fibroblasts and inhibiting fibroblast 
transdifferentiation into activated myofibroblasts (Panganiban and Day, 2011). This 
occurs through HGF-mediated up-regulation of epithelial and endothelial 
cyclooxygenase 2 (COX-2) expression that in turn promotes increased prostaglandin 
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E 2 (PGE2) synthesis. PGE2 acts as a potent inhibitor of TGF-β, the major inducer of 
fibroblast transdifferentiation (Thomas et al., 2007, Lee et al., 2008). Moreover, HGF 
has been described to directly counteract TGF-β actions through up-regulation of the 
endogenous TGF-β-signaling inhibitor, Smad 7. This leads to suppression of epithelial-
to-mesenchymal transition of alveolar type II cells, thus antagonizing fibroblast 
phenotype and eliminating a potential source of fibroblasts in the diseased lung (Shukla 
et al., 2009). Above observations are not restricted to the lung and have been 
comprehensively described in experimental models of renal and hepatic fibrosis (Liu, 
2004, Mizuno and Nakamura, 2007). 
In conclusion, HGF has been described to affect various cell types in a specific manner 
that leads to improved function of different organs and reduction of fibrotic remodeling. 
In the lung, HGF is well known for its TGF-β-counteracting properties, being largely 
responsible for diminished fibroblast expansion and suppression of 
fibroblast/myofibroblast phenotype in fibrotic lesions. However, further understanding 
of mechanisms driving HGF protective activity on endothelial and especially alveolar 
epithelial cells is necessary for developing effective and multi-targeted cure. Based on 
the fact that AECs are the primary site of the initial injury, upon which they acquire 
hyperplastic phenotype and become source of important pro-fibrotic cytokines, AECs 
seem to be a crucial target for further investigation to create an integrated treatment 
options for IPF patients. 
 
 
Figure 1.6: Mechanisms of the anti-fibrotic action of HGF in various organs (adapted from 
Panganiban et al., 2011). 
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1.2.3 Role of HGF in lung cancer 
 
Lung cancer is a multifaceted disease that can be divided in two major histological 
subtypes: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), 
which can be further subdivided in adenocarcinomas, squamous cell, bronchioalveolar 
and large cell carcinomas (Larsen et al., 2011). In general, advanced lung cancer is an 
aggressive malignancy with a poor prognosis. It develops via a multistep process 
involving tumor suppressors as well as oncogenes that trigger complex aberrations 
leading to the disruption of the normal balance of cellular life and death (Bai and Wang, 
2013). The HGF/c-Met have been shown to stimulate a number of signaling molecules 
affecting cellular motility, growth, invasion, differentiation and angiogenesis (Sadiq and 
Salgia, 2013). A number of studies have reported HGF and/or c-MET over-expression 
as well as multiple c-MET activating mutations to be implicated in various oncogenic 
processes, in the lung inclusively (Cecchi et al., 2012, Feng et al., 2012). Amplification 
of the c-Met encoding gene have been found in several types of lung cancer, including 
NSCLC where it occurs in up to 20% of the patients and negatively correlates with 
survival (Cappuzzo et al., 2009). Enhanced c-Met activation and persistent HGF/c-Met 
signaling leads to increased transforming potential via STAT3-mediated anchorage 
independent cell growth, Ras-mediated mitogenesis and PI3K-mediated inhibition of 
apoptosis (Mizuno and Nakamura, 2013).  
 
1.3 Cell death 
1.3.1 Diversity of cell death processes 
 
Cell death represents a key physiological process and is considered fundamental during 
development and aging as well as for maintaining tissue homeostasis in adult organism. 
Among others, cell death plays an important role during wound healing and repair via 
removal of activated inflammatory cells as well as myofibroblasts that are no longer 
essential at the site of injury. There are multiple factors determining cell fate, including 
the type and the intensity of the stimulus and the type of the affected cell.  
The best understood and most common form of cell death is apoptosis, a coordinated 
and energy-dependent process that involves the activation of specific cysteine proteases 
called caspases and a complex cascade of events leading to cell removal. 
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Morphologically, apoptosis is characterized by cell shrinkage, the nuclear and 
cytoplasm condensation, DNA fragmentation and formation of apoptotic bodies 
containing cellular components with almost no concomitant inflammatory reaction 
(Favaloro et al., 2012). The apoptotic cascade can be initiated via two major molecular 
pathways: the extrinsic or death receptor-mediated pathway and the intrinsic or 
mitochondrion-mediated pathway (Figure 1.7). Triggering of either pathway leads to 
executive pathway activation via proteolytical cleavage of down-stream caspases 
(Caspase 3, 6 and 7) which in turn results in the activation of proteases responsible for 
degradation of chromatin, as well as nuclear and cytoskeletal components. The last 
phase of programmed cell death (PCD) is the phagocytosis of an apoptotic cell. 
Expression of surface markers, such as phosphatidylserines Annexin I and V enables 
early recognition by macrophages or other neighboring cells and facilitates cell 
degradation (Elmore, 2007). 
Growing evidence indicates that the process of caspase activation is not the sole 
determinant of life and death decisions. Programmed cell death can be mediated via 
other executive proteases, e.g. calpains, cathepsins and endonucleases. It has been 
observed that upon excessive autophagy cells may be triggered into PCD without 
activation of caspases (Broeker et al., 2005).  
Necrosis stands for another form of cell death that can be described in contrast to PCD 
as uncontrolled and passive. Necrosis is an unintended process caused by an external 
stimulus. It is characterized by increase in cell volume followed by enlargement of 
organelles and direct disruption of membrane integrity. This process is associated with a 
release of cellular components leading to inflammatory reaction in adjacent tissue 
(Rastogi et al., 2009).  
 
1.3.2 Extrinsic pathway 
 
Extrinsic pathway of apoptosis is activated by extracellular signals that result in the 
binding of specific ligands to the transmembrane receptors belonging to the tumor 
necrosis factor (TNF) receptor superfamily, such as TNF-α or Fas ligand (FasL) with 
their respective receptors, TNF receptor 1 (TNFR1) or Fas receptor (FasR). TNF-family 
members share conserved extracellular domains and a cytoplasmatic death domain 
which is responsible for the signal transduction. The cascade of events is similar for all 
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known death receptors. Upon ligand-receptor interaction, cytoplasmatic adapter proteins 
are recruited. Depending on the type of the receptor, a specific adapter protein is 
recruited. In the FasL/FasR-mediated signal transduction, binding of the adapter 
molecule Fas-associated protein with a death domain (FADD) occurs. This enables an 
assembly of a large multi-protein complex termed a death-inducing signaling complex 
(DISC) at the plasma membrane, which in turn results in the activation of initiator Pro-
caspase 8. Additionally, FADD contains a highly conserved death effector domain that 
binds directly to a homologous region of Pro-caspase 8 leading to its cleavage. Once 
Caspase 8 is activated, the execution phase of apoptosis is triggered (Favaloro et al., 
2012, Kaufmann et al., 2012). 
 
1.3.3 Intrinsic pathway 
 
Intrinsic pathway of apoptosis is associated with a receptor-independent cellular 
response to a wide variety of extracellular factors as well as internal stimuli, including 
reactive oxygen species (ROS), ER stress, radiation, DNA damage, viral infections and 
depletion of growth factors or cytokines. These multiple forms of cellular stress 
converge on the level of the mitochondria and lead to the mitochondrial outer 
membrane permeabilization (MOMP) and release of pro-apoptotic molecules, e.g. 
Cytochrome c (Cyt c), direct IAP binding protein with low pI (Smac/DIABLO) and 
serine protease high temperature requirement protein A2 (HtrA2) into cytosol. Cyt c, 
after being released from the intermembrane space of mitochondria, binds to an adaptor 
molecule termed apoptotic protease activating factor 1 (Apaf-1), which oligomerizes 
and recruits Pro-caspase 9, thus forming the apoptosome. Additionally, Smac/DIABLO 
further stimulates caspase activation by binding and thus neutralizing inhibitor of 
apoptosis proteins (IAPs). At the same time, nuclear translocation of endonucleases, 
including AIF and Endonuclease G, released from mitochondria leads to DNA 
fragmentation and advanced chromatin condensation. This results in activation of the 
executive phase through cleavage of Pro-caspase 3 (Elmore, 2007, Bai and Wang, 
2013). 
The Bcl-2 family proteins are essential regulators of the intrinsic pathway of apoptosis. 
Complex interactions between specific members of the family determine the integrity of 
the outer mitochondrial membrane and control of the cell fate. Additionally, Bcl-2 
Introduction 
16 
family member Bid is being proteolytically activated by Caspase 8, which constitutes an 
important link between the intrinsic and extrinsic apoptosis pathways (Cory and Adams, 
2002). 
 
 
Figure 1.7: Schematic representation of extrinsic and intrinsic apoptotic pathways. 
The extrinsic pathway is mediated by caspase-8 whereas the intrinsic pathway is mediated by caspase-9. 
FADD is an adaptor protein that couples death receptors, such as FasR, to Caspase 8. The two pathways 
are interconnected by truncated BID (tBID) cleaved by active Caspase 8. Bcl-2 and Bcl-xL  inhibit the 
loss of mitochondrial membrane potential, whereas Bax/Bak mitochondrial membrane permeabilization. 
Cytochrome c is released from the mitochondria and together with Apaf-1 and Pro-caspase-9 form the 
apoptosome. SMAC/Diablo is also released from the mitochondria and blocks the effect of apoptosis 
inhibitory proteins, IAPs which promotes caspase activation. (Adapted from Hotchkiss and Nicholson, 
2006) 
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1.4 Bcl-xL as a Bcl-2 family member 
 
Bcl-xL (Bcl-2 related gene, long isoform) is a pro-survival protein that belongs to B cell 
CLL/lymphoma-2 (Bcl-2) family of proteins involved in mitochondrial control of 
apoptosis. The family comprises of proteins that share a three-dimensional structure and 
contain at least one Bcl-2 homology (BH) region. They can be functionally classified 
into three groups: anti-apoptotic, pro-apoptotic (also termed as effector proteins) and 
BH3-only proteins (Figure 1.8 A). Anti-apoptotic Bcl-2 proteins, including Bcl-2, Bcl-
xL, Bcl-w and myeloid cell leukemia-1 (Mcl-1), contain four BH domains (BH 1-4) and 
are mainly localized in the outer mitochondrial membrane (OMM). However, they may 
also be present in the cytosolic fraction or embedded in the ER. They are able to directly 
bind and sequester the pro-apoptotic proteins, thus preserving OMM integrity and 
preventing apoptosis. Bcl-2-associated x protein (Bax) and Bcl-2 antagonist killer (Bak) 
are two major representatives of pro-apoptotic multi-BH (BH 1-4) Bcl-2 related 
proteins. Whereas activation of Bax results from highly regulated, multistep process that 
requires its translocation into mitochondrial membrane, Bak is constitutively inserted 
into OMM. Oligomerization of Bax and Bak triggered by various mechanisms directly 
promotes MOMP, Cytochrome c release and apoptosis. The BH3-only proteins, e.g. 
(Bcl-2-interacting domain death agonist) Bid, (Bcl-2 interacting mediator of cell death) 
Bim, (Bcl-2 antagonist of cell death) Bad, p53 up-regulated modulator of apoptosis 
(Puma) and Noxa, are pro-apoptotic and function as initial sensors that integrate and 
transmit apoptotic signals to other Bcl-2 family members. Except Bid, the BH3-only 
proteins appear to lack a close evolutionary relationship to the multi-BH members of 
Bcl-2 family. However, they posses a highly conserved short motif called BH3, that 
allows them to bind and regulate both, the anti- and pro-apoptotic Bcl-2-related proteins 
and to promote cell death. The BH3-only proteins Bad, Noxa and Puma, which all have 
the ability to bind only the anti-apoptotic Bcl-2 family members, are referred to as 
“sensitizers/de-repressors”, since they lower the threshold for Bax/Bak activation, but 
do not induce apoptosis in a direct manner. The BH3-only proteins Bid and Bim, that 
can as well as interact with the effector proteins and directly induce oligomerization of 
Bax/Bak, are termed “direct activators” (Adams and Cory, 1998, Chipuk et al., 2010, 
Youle and Strasser, 2008). The main event upon apoptotic stimuli is the proteolytical 
activation of Bid, predominantly by Caspase 8, and translocation to mitochondria of the 
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truncated form of Bid (tBid), where it’s able to recruit and induce conformational 
change of Bax leading to Bax insertion and Bax/Bak oligomerization in the OMM 
(Martinou and Youle, 2011) (Figure 1.8 B).  
 
 
Figure 1.8: Bcl-2 family classification and membrane permeabilization. 
(A) Bcl-2 family members can be divided into three groups: pro-apoptotic, anti-apoptotic and BH3-only 
proteins, based on their function and structural homology. BH regions, transmembrane (TM) domains as 
well as known α-helical structures are indicated. (B) Proposed model of Bax activation. Soluble Bax 
interacts directly with activated Bid and directly with OMM to promote MOMP and subsequent 
mitochondrial content release. (Adapted from Chipuk et al., 2010, Cory and Adams, 2002). 
 
Bcl-xL is a potent negative regulator of apoptosis. It promotes cell survival by 
regulating the electrical and osmotic homeostasis of mitochondria, and prevent Cyt c 
redistribution from the intermembrane space into the cytosol. Additionally, Bcl-xL has 
been shown to regulate these events also independently from caspases (Vander Heiden 
et al., 1997). Bcl-xL has been reported to inhibit MOMP by competing with Bax via 
direct and indirect mechanisms. Bcl-xL has been shown to directly bind to Bax by its 
C-terminal membrane anchor. Moreover, it has been described that Bcl-xL can be 
translocated from the cytosol to the mitochondria after Bid activation, where it is 
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capable of sequestering tBid into stable complexes. This prevents activation and further 
recruitment of Bax to OMM, which in turn suppresses MOMP and subsequent apoptosis 
at the relatively advanced stage (Billen et al., 2008).  
 
1.5 Role of Bcl-xL and HGF in tissue fibrosis 
 
Accumulating evidence suggests an important role of epithelial apoptosis in the 
development of tissue fibrosis. Current hypothesis states that chronic and deregulated 
apoptosis of alveolar epithelial cells triggered by repetitive injury may be the primary 
cause of IPF and the driving force of the disease progression (Jenkins et al., 2012). 
Since Bcl-xL is a potent regulatory protein involved in controlling mitochondrial 
pathway that can be activated by various stimuli, including oxidative damage and ER 
stress, it may play an important role in pathogenesis of pulmonary fibrosis. 
It has been reported that spontaneous and continuous apoptosis of hepatocytes induced 
by specific knock-down of Bcl-xL in those cells, triggered liver fibrotic responses in 
vivo. Bcl-xL deficient mice showed increased production of TGF-β1 and collagen 
deposition. In addition, in vitro exposure of macrophages as well as normal hepatocytes 
to apoptotic hepatocytes lacking Bcl-xL stimulated TGF-β1 production, resembling the 
situation during human liver fibrosis/cirrhosis (Baer et al., 1998, Takehara et al., 2004). 
Moreover, Zhang et al. observed that HGF promotes survival of renal tubular epithelial 
cells exposed to oxidative stress through increased Bcl-xL expression combined with 
Bad phosphorylation (Zhang et al., 2008). The role of Bcl-xL during development 
and/or progression of pulmonary fibrosis needs to be yet elucidated. In a recent study it 
was found that Bcl-xL is the predominant isoform expressed in the lung and the only 
isoform detected in alveolar epithelial cells. The loss of Bcl-xL in AECII shifted the 
lung towards a pro-apoptotic state defined by decrease of Mcl-1 and increase of Bak 
expression, as well as higher sensitivity of the respiratory epithelium to hyperoxia 
(Staversky et al., 2010). These observations suggest that Bcl-xL may be an important 
factor mediating protection of AECII during oxidative damage. Moreover, studies 
indicate that HGF signaling may be involved in the regulation of Bcl-2 family 
expression. In the rat model of ischemia/reperfusion injury, application of exogenous 
HGF improved survival of myocardiocytes, what was correlated with increased 
expression of Bcl-xL specifically in the ischemic areas (Nakamura et al., 2000). 
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However, HGF showed a protective effect on lung endothelial cells after oxidative 
damage, through blocking Bid and Bax translocation to mitochondria and inhibiting 
Caspase 8 activation (Wang et al., 2004).  
Taken together, these data implicate that there might be a link between HGF and 
Bcl-xL, which could potentially lead to the suppression of fibrotic remodeling in the 
lung and result in improved pulmonary function. Thus, further understanding of the 
mechanism of apoptosis-induced fibrogenesis appears necessary for development of 
proper therapeutic options for controlling progression of pulmonary fibrosis and 
preventing complete organ failure. 
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2 Aim of the study 
 
It is well established that HGF possesses anti-fibrotic properties. Studies on animal 
models have provided strong evidence that supplementation of exogenous HGF has a 
beneficial role in fibrotic disorders in various organs, including the lung. It has been 
reported that HGF can act via multiple direct and indirect mechanisms linked to 
improved cellular survival and reduced of myofibroblast accumulation. HGF-elicited, 
pro-survival pathways have yet not been investigated in detail in lung epithelial cells. In 
the liver and heart, Bcl-xL protein has been suggested to be a part of an important anti-
apoptotic mechanism involved in resolution of fibrotic remodeling of these organs, 
however it remains to be elucidated in the lung. Since the HGF signaling via c-Met 
receptor has been proposed to regulate the expression of Bcl-2 family members, the 
present study was performed to evaluate the potential role of Bcl-xL in HGF-mediated 
epithelial protection in IPF. 
 
In this context, the aim of this study was: 
 
1. to characterize Bcl-xL expression and its cellular localization in lung tissues of 
IPF patients in comparison to organ donors 
2. to assess the Bcl-xL expression pattern in highly remodeled areas in comparison 
to still normal-appearing regions of IPF lung tissue 
3. to investigate whether HGF mediates pro-survival effect on alveolar epithelial 
cells driven into apoptosis by oxidative stress, ER stress and Fas ligand-triggered 
activation of cell death receptor 
4. to assess the potential role of Bcl-xL in this regard.  
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3 Materials and methods 
3.1 Materials 
3.1.1 Reagents 
 
Name Company 
2-(4,2-hydroxyethyl)-piperazinyl-1-
ethansulfonate (HEPES) 
Sigma Aldrich, Germany 
2-amino-2-hydroxymethyl-1,3-propanediol 
(Tris) 
Roth, Germany 
2-Mercapto-ethanol Sigma Aldrich, Germany 
Acrylamide solution, Rotiphorese® Gel 30  Roth, Germany 
Albumine, Bovine Serum (BSA) Roth, Germany 
Ammonium Persulfate (APS) Roth, Germany 
Bromophenol Blue Sigma Aldrich, Germany 
Citric Acid Thermo Scientific, USA 
c-Met Inhibitor, PHA-665752 Sigma Aldrich, Germany 
Cytotoxicity Detection Kit (LDH) Roche, Germany 
DharmaFECT 1  Thermo Scientific, USA 
Dimethyl Sulfoxide (DMSO) Sigma Aldrich, Germany 
DMEM-F12 Medium Gibco, Germany 
Dulbecco’s Phosphate Buffered Saline (PBS) PAA, Austria 
Ethanol 99,5% Roth, Germany 
Ethylenediamine-tetraacetic Acid (EDTA) Sigma Aldrich, Germany 
Fas Ligand (FasL) Life Sciences, Germany 
Fetal Calf Serum (FCS) Roth, Germany 
Glycergel® Mounting Medium Dako, Denmark 
Glycerole Roth, Germany 
Glycine 99% Roth, Germany 
Hepatocyte Growth Factor  R&D Systems, USA 
Hydrobeta-estradiole Sigma Aldrich, Germany 
Hydrochloric Acid (HCl) 32% Sigma Aldrich, Germany 
Hydrocortisone Sigma Aldrich, Germany 
Hydrogen peroxide Roth, Germany 
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Insulin, Transferrin, Sodium Selenite (ITS) PAN Biotech, Germany 
iQ™ SYBR® Green Supermix Bio-Rad, USA 
Isoflurane Baxter, Germany 
KH2PO4 Merck, Germany 
L-Glutamine Gibco, Germany 
Methanol 99,9% Roth, Germany 
N,N,N’,N’-tetramethyl-1,2-diaminomethane 
(TEMED) 
Sigma Aldrich, Germany 
Na2HPO4x2H2O Merck, Germany 
Na-deoxycholate Merck, Germany 
Nucleotide Mix (dNTPs) Qiagen, Germany 
Oligo(dT) Primer Roche, Germany 
PageRuler™ Prestained Protein Ladder Thermo Scientific, USA 
Paraffin, Paraplast Plus® Sigma Aldrich, Germany 
Penicillin/Streptomycin PAA, Austria 
Pierce® BCA Protein Assay Kit  Thermo Scientific, USA 
Pierce® ECL Plus Western Blotting Substrate Thermo Scientific, USA 
Potassium Chloride (KCl) Merck, Germany 
Protease Inhibitor Cocktail Complete™ Roche, USA 
Restore™ Western Blot Stripping Buffer Thermo Scientific, USA 
RNase Inhibitor Roche, Germany 
Rnase-free Water Qiagen, Germany 
Roti®-Histofix 4% Roth, Germany 
Saccharose Roth, Germany 
siRNA, Scrambled RNA Thermo Scientific, USA 
Skim Milk Powder Fluka, Germany 
Sodium Chloride (NaCl) Sigma Aldrich, Germany 
Sodium Citrate Tribasic Dihydrate Sigma Aldrich, Germany 
Sodium Citrate Tribasic Dihydrate Sigma Aldrich, Germany 
Sodium Dodecyl Sulfate (SDS) Sigma Aldrich, Germany 
Sodium Hydroxide (NaOH) Sigma Aldrich, Germany 
Staurosporine Calbiochem, Germany 
Thapsigargin Invitrogen, Germany 
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Triton-X-100 Sigma Aldrich, Germany 
Trypan Blue Sigma Aldrich, Germany 
Trypsin/EDTA PAA, Austria 
Tween-20 Sigma Aldrich, Germany 
ZytoChem HRP-DAB Kit ZytoMed, Germany 
 
 
3.1.2 Equipment  
 
Name Company 
Analytical Balance Mettler Toledo, Switzerland 
Cell Culture 6-well Plates Greiner Bio-One, Germany 
Cell culture centrifuge, Universal 30RF Hettich, Germany 
Cell Culture Hood HERAsafe Hereaus, Germany 
Cell Culture Incubator, HERAcell 150i Thermo Scientific, Germany 
Cell Scrapers Costar, USA 
Centrifuge, Mikro 200R Hettich, Germany 
Cooling Plate, EG 1150C Leica, Germany 
Culture Slides BD Falcon, USA 
Dry Block Thermostat Ditabis, Germany 
Electrophoresis Chamber Bio-Rad, USA 
Falcon Roller CAT, Germany 
Falcon tubes BD Falcon, USA 
Freezer +4° Bosch, Germany 
Freezer -20° Bosch, Germany 
Freezer -80°C Hereaus, Germany 
Gel Blotting Paper GE Healthcare, UK 
Glass Slides, Automat Star Langenbrinck, Germany 
Glass slides, SuperFrost Plus Langenbrinck, Germany 
Heating Oven, FunctionLine Hereaus, Germany 
Heating Plate, HI 1220 Leica, Germany 
iCycler IQ™ Thermocycler Bio-Rad, USA 
Light Microscope, Axiovert 25 Carl Zeiss, Germany 
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Magnetic Stirrer Heidolph, Germany 
Microsprayer Penn-Century Inc, USA 
Microtome  
Mirax Scan Carl Zeiss, Germany 
Multipipette Eppendorf, Germany 
NanoDrop PeqLab, Germany 
Neubauer Chamber Optik Labor, Germany 
Nitrile gloves Ansell, Germany 
Paraffin Embedding Module, EG 1140H Leica, Germany 
PCR Thermocycler Bio-Rad, USA 
Petri Dishes Sarstedt, Germany 
Pipette Tips Biozym, Germany 
Pipettes Eppendorf, Germany 
Power Supply, Consort Roth, Germany 
PVDF Transfer Membrane, Hybond™-P GE Healthcare, UK 
Scapels Feather, Germany 
Shaker, Duomax  Heidolph, Germany 
SpectraFluor Plus Tecan, Germany 
Spin-down VWR International, Germany 
Syringe Filters 0,20um Sarstedt, Germany 
Syringes Braun, Germany 
Timer Roth, Germany 
Toploader Balance Mettler Toledo, Switzerland 
Trans-Blot® SD Bio-Rad, USA 
Vacuum Driven Bottle Filter, 33mm, 45mm Millipore, USA 
Vacuum-based Tissue Processor, ASP 300S Leica, Germany 
Vortex Machine VWR International, Germany 
Water Bath  Julabo, Germany 
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3.2 Methods 
3.2.1 RNA isolation 
 
Total RNA was isolated from cells using RNeasy® Plus Mini Kit (QIAGEN, Germany) 
according to manufacturer’s instructions. In short, cells suspended in lysis buffer 
containing 1% 2-mercaptoethanol, were passed through a shredding column for lysis 
and homogenization. Ethanol was then added to promote binding of RNA to the 
membrane of the RNeasy spin column. During the next steps, contaminants were 
washed away and high-quality RNA was eluted with RNase-free water. Purity and 
concentration of RNA were measured based on its absorbance at 260 nm and 280 nm 
with a NanoDrop® spectrophotometer. If not used immediately for experiments, RNA 
samples were stored at -80°C. 
 
3.2.2 Reverse transcription reaction 
 
Reverse transcription (RT) was performed to obtain high yields of full length cDNA 
with RNA as a starting template. cDNA was synthesized from previously isolated RNA 
using Omniscript® Reverse Transcription Kit. 2 μg of total RNA was added to RNase-
free water up to a volume of 14 μl and gently mixed. Then 6 μl of reaction mixture was 
added, each sample vortexed, spinned down and left standing at room temperature for 
10 min for annealing to occur. Next, tubes were transferred to a heating block and kept 
for 65 min at 37°C. The newly obtained cDNA was used for further experiments, 
otherwise stored at -20°C. 
 
RT reaction component Volume Final concentration 
10xRT Buffer 2 μl 1x 
5mM dNTP mix 2 μl 0,5 mM 
50uM Oligo d(T) primers 0,5 μl 1,25 μM 
RNase inhibitor (20U/ul) 0,5 μl 0,5 U 
Omniscript™ RT (4U/ul) 1 μl 2 U 
RNase-free water up to total volume of 20 μl - 
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3.2.3 Real-time polymerase chain reaction 
 
Real-time PCR (qPCR) is an enzymatic method used for both qualitative and 
quantitative analysis of nucleic acid. The accumulation of amplified product is 
measured as the reaction progresses, after each cycle. This is achieved by the inclusion 
of a fluorescent reporter dye into amplicons in each reaction, which leads to increased 
fluorescence signal with increased amount of DNA product. Amplification of cDNA 
was performed according to the manufacturer’s instructions provided with iQ™ 
SYBR® Green Supermix (Bio-Rad) that contains hot-start iTaq DNA polymerase, 
dNTPs, MgCl2, SYBR® Green I dye, enhancers, stabilizers and fluorescein. The qPCR 
reaction mix was prepared as follows: 
 
qPCR reaction component Volume Final concentration 
iQ™ SYBR® Green Supermix 10 μl 1x 
Forward primer * (10pmol/ul) 0,5 μl 0,25 nM 
Reverse primer * (10pmol/ul) 0,5 μl 0,25 nM 
Water 7 μl - 
cDNA template (5ng/ul) 2 μl 10 ng per reaction 
 
* Primer sequences:  
Bcl-xL (NM_009743.4) forward primer 5’ TGTCTGGTCACTTCCGACTG 3’, reverse primer 
5’ GCTGGGACACTTTTGTGGAT 3’ 
β-actin (NM_007393.3) forward primer 5’ CTACAGCTTCACCACCACAG 3’, reverse primer 
5’ CTCGTTGCCAATAGTGATGAC 3’ 
 
Reaction components were mixed on ice in a total volume of 20 μl and transferred to a 
thermocycler. PCR was performed using a iCycler IQ™ Single Color Real-Time PCR 
Detection System (Bio-Rad) monitoring by an iQ™ 5 Optical System Software. 
Programmed steps are listed below: 
 
Step Time Temperature 
Polymerase activation and DNA denaturation 3 min 95°C 
Amplification 
35 cycles 
Denaturation 15 sec 95°C 
Annealing/Elongation 30 sec 59°C 
Melt curve analysis 10 sec/step 
55-95°C 
0,5°C increment 
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Before levels of nucleic acid targets could be quantified, the raw data was analyzed and 
baseline and threshold values set. The background component of the signal was 
removed by the software algorithm. The threshold was adjusted to a value above the 
background and below the plateau of the amplification curve, and threshold cycle (Ct) 
values were obtained. To normalize data for the amount of template used, qPCR on the 
identical template, but with primers specific for the endogenous reference gene (house-
keeping gene: beta-actin) was performed simultaneously.  
 
ΔCt = Ct (endogenous reference gene) – Ct (target gene) 
 
The specificity of products was determined by their melting curves to get the highest 
specific amplification and the lowest background amplification. 
 
3.2.4 Protein isolation 
3.2.4.1 Protein isolation from cultured cells 
 
Cells were lysed with protein extraction buffer containing protease inhibitor. Lysates 
were incubated on ice for 30 min and then centrifuged for 10 min at 13000xg at 4°C. 
Supernatants were transferred to new tubes and stored at -80°C. 
 
Protein extraction buffer Final concentration 
Tris 50 mM 
NaCl 150 mM 
EDTA 5 mM 
Triton-X-100 1% 
Na-deoxycholate 0,5% 
Protease inhibitor cocktail Complete™ 4% 
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3.2.4.2 Human samples and patient data analysis 
 
Tissue samples were obtained with the written consent of the patients. The study was 
approved by the local research ethics committee of Justus-Liebig-University School of 
Medicine (No. 31/93, 84/93, 29/01), provision of patients biospecimen was approved by 
University of Vienna Hospital ethics committee (EK-No. 076/2009) and European IPF 
Registry (No. 111/08, “eurIPFreg”). HGF expression in lung homogenates was studied 
in two groups of subjects: 18 patients with IPF (mean age 50,2 ± 12,2 years; 3 females, 
15 males) and 10 control patients (mean age 45,4  ± 12,7 years; 3 females, 5 males, data 
not available for 2 control patients). Bcl-xL expression in lung homogenates was 
studied in two groups of subjects: 20 patients with IPF (mean age 50,9 ± 11,9 years; 3 
females, 17 males) and 10 control patients (mean age 45,4 ± 12,7 years; 3 females, 5 
males, data not available for 2 control patients). BAL fluid analysis was performed on 
11 patients with IPF (mean age 63,8 ± 12,8 years; 3 females, 8 males) and 11 control 
subjects (mean age 36,9 ± 19,9 years; 6 females, 4 males). Diagnosis of sporadic IPF 
was made according to ATS/ERS International Multidisciplinary Consensus 
Classification of the Idiopathic Interstitial Pneumonias and a usual interstitial 
pneumonia (UIP) pattern was proven in all 20 explanted lungs. Non-utilized control 
lungs or lobes from donors fulfilled transplantation criteria. 
 
3.2.4.3 Protein isolation from lung tissue 
 
Lung tissues used for analysis were acquired from IPF patients after lung 
transplantation. Samples taken from peripheral regions of the lung were collected, 
shock-frozen in liquid nitrogen and stored at -80°C. As controls, donor lung tissues not 
utilized because of size incompatibility were used. About 70 mg of tissue was taken for 
protein isolation, put into micro packaging vials containing 1,4 mm and 2,8 mm 
zirconium oxide beads and protein extraction buffer with protease inhibitor. Tissues 
were homogenized at high speed in Precellys® (2 cycles of 20 sec at the speed of 
5500 rpm) according to manufacturer’s instructions. Samples were put on ice for 30 min 
and subsequently centrifuged for 10 min at 13000xg at 4°C to pellet the debris. 
Supernatants were transferred to new tubes and stored for further analysis at -80°C. 
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3.2.5 Protein quantification 
 
Protein concentration was determined spectrophotometrically using Pierce® BCA 
Protein Assay Kit according to manufacturer’s instructions. The assay is used for 
colorimetric detection and quantification of total protein compared to a protein standard. 
In the first step the biuret reaction takes place, where copper is chelated with protein in 
an alkaline environment, forming light blue complexes. In the second step the 
bicinchoninic acid (BCA) reacts with reduced cuprous ions, resulting in intense purple-
colored reaction product which exhibits a strong linear absorbance at 562 nm with 
increasing protein concentrations. The absorbance was measured by ELISA-plate reader 
(SpectraFluor Plus, Tecan). BSA in ten different concentrations ranging from 1,5 mg/ml 
to 7,8 μg/ml was used as a standard. 
 
3.2.6 SDS polyacrylamide gel electrophoresis 
 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed to separate 
extracted proteins according to their sizes in an electric field. 50 μg of protein was 
mixed with loading buffer containing 2-mercaptoehtanol (added freshly) and 
denaturated in heating block at 95°C for 10 min.  
 
Loading buffer (4x) Concentration 
SDS 5% (w/v) 
Tris/HCl, pH 6,8 156 mM 
Glycerol 40% (v/v) 
Bromophenol blue 0,01% (w/v) 
2-mercaptoethanol 5% (v/v) 
Water - 
 
Samples were shortly vortexed before loading into gel pockets. Depending on the size 
of the target protein, 8%, 12% or 15% gels were used.  
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Separating gel Concentration 
Acrylamide/Bisacrylamide (30%/0,8%) 8% / 12% / 15% 
Tris/HCl, pH 8,8 375 mM 
SDS 0,1% (w/v) 
TEMED 0,1% (v/v) 
APS 0,05% (w/v) 
Water - 
 
Stacking gel Concentration 
Acrylamide/Bisacrylamide (30%/0,8%) 4% 
Tris/HCl, pH 6,8 125 mM 
SDS 0,1% (w/v) 
TEMED 0,1% (v/v) 
APS 0,1% (w/v) 
Water - 
 
Electrophoresis was carried out in SDS-running buffer at 85V until the bands of the 
Prestained Protein Ladder were properly separated. 
 
SDS-running buffer  Concentration 
Tris 25 mM 
Glycine 192 mM 
SDS 0,1% (w/v) 
Water - 
 
3.2.7 Immunoblotting 
 
Immunoblotting is an analytical technique using antibodies to detect and identify target 
proteins among a number of unrelated protein species in a sample. Identification is 
based on a antigen-antibody specific interactions, which is further visualized using 
secondary antibodies labeled with enzymes or radioisotopes. 
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3.2.7.1 Protein blotting 
 
Proteins resolved by SDS-PAGE were transferred onto a 0,45 μm polyvinylidene 
fluoride (PVDF) membrane in semi-dry blotting chamber. The membrane was activated 
before use in pure methanol. Transfer was performed in transfer buffer at 1mA/1cm
2
 for 
90 min. 
 
Transfer buffer  Concentration 
Tris 20 mM 
Glycine 159 mM 
Methanol 20% (v/v) 
Water - 
 
3.2.7.2 Protein detection 
 
To minimize background, membranes were blocked in 5% Skim Milk in wash buffer 
(TBS-T) for 1h 20 min at room temperature. Subsequently, they were transferred into 
falcon tubes with appropriate primary antibodies (see Appendix) dissolved in 5% Skim 
Milk and incubated overnight at 4°C. 
After washing 3 times for 10 min in TBS-T buffer, membranes were incubated with 
horseradish peroxidase-labeled secondary antibodies for 50 min at room temperature 
and again washed 3 times for 10 min. Specific bands were visualized by 
chemiluminescence using a Pierce ECL Plus Western Blotting Substrate and a 
ChemoCam detection system. For re-probing, membranes were stripped in Restore™ 
Western Blot Stripping Buffer for 20 min at room temperature and subsequent protein 
detection was performed as described above. 
 
TBS-T buffer, pH 7,5 Concentration 
Tris 50 mM 
NaCl 50 mM 
Tween-20 0,1% (v/v) 
Water - 
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3.2.7.3 Densitometry 
 
To quantify the amount of target protein in each sample, the intensity of bands was 
measured using AlphaEaseFC™ software. Beta-actin was used as loading control. 
 
3.2.7.4 Coomassie Brilliant Blue staining 
 
Coomassie Brilliant Blue permanently stains proteins bound to PVDF membrane with a 
detection limit of about 1,5 μg of protein. In order to obtain loading control for Western 
blot analysis of BAL fluid samples, coomassie staining was performed after detection of 
primary target. Membranes were briefly washed with distilled water and subsequently 
put into the staining solution (composition described below) for few seconds.  
 
Staining solution Concentration 
Methanol 50% (v/v) 
Acetic acid 5% (v/v) 
Coomassie Brilliant Blue R-250 0,25% (v/v) 
Water - 
 
Stained membranes were washed multiple times in destaining solution. When the 
background colour was effectively removed, membranes were rinsed with water and 
scanned. 
 
Destaining solution Concentration 
Isopropanol 28% (v/v) 
Acetic acid 5% (v/v) 
Water - 
 
3.2.8 Immunohistochemistry 
 
Immunohistochemistry (IHC) was performed to detect and localize the expression of 
specific antigens in lung tissue. Small pieces (~2 cm x 2 cm) of lung tissue from 
patients with IPF and donors were fixed with phosphate-buffered formaldehyde solution 
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(Roti®-Histofix 4%, pH 7,0) overnight at 4°C. Afterwards the tissue blocks were 
transferred into an embedding cassette and stored in phosphate-buffered saline (PBS) at 
4°C.  
 
PBS x10, pH 7,4 Concentration 
NaCl 1,37 M 
KCl 26,8 mM 
Na2HPO4x2H2O 64,6 mM 
KH2PO4 14,7 mM 
Water - 
 
Subsequently, dehydration in a vacuum-based tissue processor (ASP 300S, Leica) was 
performed overnight and tissue blocks were embedded in warmed to 65°C paraffin with 
use of Leica embedding module (EG 1140H, Leica). After cooling on a cooling plate 
(EG 150C, Leica), serial lung tissue sections (thickness of 3 μm) were cut with fully-
automated rotation microtome and mounted on positively-charged glass slides. Finally, 
slides were dried on a pre-warmed heating plate (HI 1220, Leica), then incubated for 8-
12h at 37°C in a heating oven and stored at room temperature. Directly before IHC 
procedure, slides were heated-up to 60°C in heating oven (FunctionLine, Hereaus) and 
subsequently deparaffinized in xylene for 10 min. Then they were rehydrated in 
descending ethanol concentrations (99,6% > 96% > 80% > 70% > 50%), each 
inembation step for 3 min. Slides were washed in PBS and permeabilized by boiling in 
citrate buffer, three times for 10 min.  
 
Citrate buffer, pH 6,0 Concentration 
Sodium citrate tribasic dihydrate 10 mM 
Citric acid 109 mM 
Water - 
 
After washing in PBS, further steps were performed with the use of ZytoChem HRP-
DAB Kit according to manufacturer’s instructions. Briefly, sections were first blocked 
in blocking solution for 5 min, then incubated with primary antibodies (see Appendix) 
overnight at 4°C. Following washing in PBS, sections were incubated for 15 min with 
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biotinylated secondary antibody provided with the kit. Streptavidin HRP-conjugate was 
put on sections for 15 min and DAB dissolved in substrate buffer was used as a 
substrate for HRP. Sections were stained in parallel. Counterstaining was performed 
with haemalaun for 35 sec, followed by washing the slides in running tap water. Such 
prepared sections were mounted with Glycergel® Mounting Medium and left to air-dry. 
Stained tissue slides were digitalized with the use of a Mirax slide scanning device 
(Zeiss) and analyzed with the Mirax Viewer software. 
 
3.2.10 In vitro experiments 
3.2.10.1 Cell culture condition 
 
The mouse lung epithelial cell lines (MLE-12 and MLE-15) were obtained from ATCC, 
Manassas, USA. The rat lung epithelial cell line (RLE-6TN) was a kind gift of Dr. 
Istvan Vadász, Department of Internal Medicine, Justus Liebig University, Giessen, 
Germany. 
All cells were grown on 10 cm Petri dishes in full medium based on growth medium 
DMEM-F12, at 37°C, 5% CO2 and 95-100% humidity. 
 
DMEM-F12 Full medium  Concentration 
Hydrocortisone 10 nM 
Hydrobeta estradiole 10 nM 
ITS 5% (v/v) 
HEPES 10 mM 
L-Glutamine 2 mM 
FCS 2% 
Penicillin/streptomycin 1% 
 
After reaching a confluence of 80-90%, cells were passaged to a new Petri dish. At first, 
cells were washed with PBS and incubated for 2-3 min with 3 ml of Trypsin/EDTA 
solution. The action of trypsin was stopped by adding 15 ml of medium containing FCS 
and cells were collected to a 50 ml falcon tube and centrifuged at 1100xg for 7 min. 
Next, the supernatant was removed and cells were resuspended in 10 ml of full medium, 
counted and plated on new culture dishes. 
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For the purpose of in vitro studies, cells were seeded on 6- or 12-well plates and kept in 
full medium for 24h to enable proper attachment of the cells to the plate. Stimulation 
with hepatocyte growth factor, as well as with cell death inducers (hydrogen peroxide, 
thapsigargin, Fas ligand) was performed in serum-free medium supplemented with 5% 
ITS.  
 
3.2.10.2 Transfection with small interfering RNA 
 
Transfection with small interfering RNA (siRNA) allows to specifically inhibit protein 
expression through selective silencing of gene expression by delivery of double-
stranded RNA molecules into the cell. The siGENOME SMARTpool siRNA 
oligonucleotides specific for murine Bcl-xL mRNA were obtained from Thermo 
Scientific. Mouse lung epithelial cells (MLE-12) were transfected with 25 nM Bcl-xL-
targeting siRNA or ON-TARGETplus non-targeting siRNA #1 as a negative control.  
 
siGENOME mouse Bcl-xL Target sequence 
D-065142-01 UUAGUGAUGUCGAAGAGAA 
D-065142-02 UGAGUCGGAUUGCAAGUUG 
D-065142-03 GGAGAGCGUUCAGUGAUCU 
D-065142-04 UGGAAAGCGUAGACAAGGA 
 
Before transfection, 40000 cells were plated into each well of a 6-well plate and 
incubated overnight. Transfection procedure was performed according to 
manufacturer’s instructions. Briefly, DharmaFECT1 and siRNAs were dissolved in 
antibiotic- and serum-free medium in separate tubes and incubated at RT. After 5 min 
both reagents were mixed and incubated for another 20 min. Subsequently, the siRNA 
mix was put onto the cells in serum-containing medium. After 24h, 48h and 72h cells 
were lysed and the gene knock-down level was assessed by the use of real-time PCR 
and Western blotting. 
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3.2.10.3 Cytotoxicity assay 
 
Cytotoxicity Detection Kit (Roche) contains a colorimetric assay for the quantification 
of cell death and cell lysis, based on the measurement of lactate dehydrogenase (LDH) 
activity released from the cytosol of damaged cells into the cell-culture medium. The 
relative LDH release is directly proportional to the cell death level in an experimental 
setting. LDH assay was performed according to manufacturer’s instructions. 
Experiments were performed on 12-well plates, each well of 1 ml volume. 500 μl of cell 
supernatant was transferred into a new tube containing 500 μl of fresh full medium and 
spinned down at 1000xg for 5 min. Cells left on wells were treated for 5 min with 
500 μl of 2% Triton-X-100 in full medium. Subsequently, the reaction mix from the kit 
was added and the absorbance at 490 nm measured by an ELISA-plate reader 
(SpectraFluor Plus, Tecan). The raw data was analyzed according to the formula stated 
below and presented as a % of relative LDH release into the medium. 
 
 
 
For each sample 5 biological replicates were used and 2 independent measurements 
have been performed. 
 
3.2.12 Statistical analysis 
 
Data are expressed as the mean value ± SEM. Statistical comparisons between two 
groups were done using unpaired Student t-tests. One-way ANOVA in combination 
with a Tukey post-hoc test was performed to compare differences between multiple 
groups. Probability value of p<0,05 was considered to be statistically significant. 
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4 Results 
4.1 Analysis of human lung samples 
4.1.1 Expression of Bcl-xL in lung homogenates and BALFs from 
fibrotic and healthy lungs 
 
To investigate potential changes in the amount of Bcl-xL in human lungs during IPF, 
protein expression in homogenates and BALFs obtained from IPF patients and 
donors/healthy controls was examined. Significant increase in Bcl-xL level was 
observed in IPF homogenates compared to donor lungs (Figure 4.1 A). No detectable 
amount of Bcl-xL was found in lavage fluid samples for either IPF or controls 
containing 5 μg of total protein (Figure 4.1 B). MLE12 cell lysate has been used as a 
positive control. 
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Figure 4.1: Expression of Bcl-xL in lung samples from IPF patients and healthy subjects. 
(A) Western blot analysis of lung homogenates showing significantly increased levels of Bcl-xL in IPF 
patients compared to donors. IPFs n=20, donors n=11, N=3. (B) Western blot analysis of BAL fluids. 
IPFs n=11, controls n=11, N=2, pos: positive control, MLE-12 total cell lysate. *** p=<0,001. 
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4.1.2 Localization of Bcl-xL in lungs of IPF patients and organ donors 
 
Since we observed an increased expression of Bcl-xL protein in total lung homogenates 
from IPF patients in comparison to healthy donors, immunohistochemical staining was 
performed on lung tissue obtained from organ donors and IPF patients in order to 
determine the Bcl-xL expression pattern (Figure 4.2). 
In human IPF lung, Bcl-xL protein was highly expressed in hyperplastic alveolar type II 
cells found in the regions of dense fibrosis. It could also be detected in bronchial 
epithelial cells as indicated by co-staining with Cytokeratin 5 and cc-10, molecular 
markers for basal calls and Clara cells respectively. In donor lungs, Bcl-xL was 
similarly localized in bronchial and alveolar epithelial type II cells, however, the signal 
in control sections was much weaker when compared to fibrotic lungs, especially in 
type II cells, which is consistent with our data on the Bcl-xL protein content in lung 
homogenates (Figure 4.1 A, B).  
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Figure 4.2: Localization of Bcl-xL in lungs of IPF patients and organ donors. 
Paraffin-embedded lung section from IPF patients (A, B) and lung donors (C, D) were stained for Bcl-xL, 
Pro-SPC, cytokeratin 5 and cc-10, as indicated. Cell type markers were used as follows: pro-SPC for 
alveolar type II cell, cytokeratin 5 for basal cell, cc-10 for Clara cell. (F) Negative control. The pictures 
are representative of at least four IPF/donor subjects. Scale bars represent 100 μm and (B) 1000 μm at 
lower magnification. 
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Figure 4.2: Localization of Bcl-xL in lungs of IPF patients and organ donors. 
Paraffin-embedded lung section from IPF patients (A, B) and organ donors (C, D) were stained for Bcl-
xL, Pro-SPC, cytokeratin 5 and cc-10, as indicated. Cell type markers were used as follows: pro-SPC for 
alveolar type II cell, cytokeratin 5 for basal cell, cc-10 for Clara cell. (E) Negative control. The pictures 
are representative of at least four IPF/donor subjects. Scale bars represent 100 μm and (B) 1000 μm at 
lower magnification. 
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4.1.3 Expression of Bcl-xL in fibrotic and non-fibrotic areas of IPF 
lungs 
 
The histopathological UIP pattern is characterized by spatial heterogeneity with regions 
of normal lung architecture alternating with patchy areas of overt regions of fibrosis. 
Due to the fact that IPF is a slowly progressing, chronic disorder, we hypothesize that 
normal looking areas of a fibrotic lung may represent an early stage of the disease. 
Thus, we were interested in Bcl-xL expression pattern, especially its presence or 
absence in alveolar epithelial type II cells in remodeled versus not remodeled regions of 
the lung. To achieve that, immunohistochemical staining was performed on sections 
showing both, normal lung structure with adjacent areas of fibrosis (Figure 4.3).  
In agreement with previous results, Bcl-xL was strongly expressed in hyperplastic 
epithelial type II cells of fibrotic areas. In contrast, staining for Bcl-xL in type II cells in 
still regular imposing areas of the IPF lung appeared to be much weaker and resembled 
the expression pattern observed for donor lung (Figure 4.2 and 4.3) rather than IPF. 
 
4.1.4 Co-localization of Bcl-xL and c-Met in lungs of IPF patients 
 
Since interdependence between Bcl-xL and HGF-mediated signaling pathway in 
alveolar epithelial type II cells was one of the major questions of this study, we were 
interested in co-localization of Bcl-xL and HGF receptor, c-Met. Therefore, we 
performed immunohistological staining for Bcl-xL and c-Met on serial sections 
obtained from IPF patients (Figure 4.4).  
We observed that c-Met expression co-localized with Bcl-xL in the same bronchial and 
alveolar epithelial cell populations. Additionally, c-Met receptor was expressed by 
myofibroblasts present in fibrotic remodeled areas as assessed by α-smooth muscle 
actin co-staining (data not shown). 
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Figure 4.3: Expression of Bcl-xL in fibrotic and non-fibrotic areas of lungs of IPF patients. 
Immunohistochemical staining of paraffin-embedded lung sections from IPF patients. Expression of 
Bcl-xL in alveolar type II cells (pro-SPC positive) in (A) fibrotic area representing end stage of disease 
versus (B), still regular apearing lung regions, potentially representing early stage of IPF. Pictures 
represent regions of the same section. Experiment was performed on samples from four different IPF 
patients. Scale bars represent 200 μm. 
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Figure 4.4: Co-localization of Bcl-xL and c-Met in lungs of IPF patients. 
Representative staining results of paraffin-embedded lung sections from IPF patients showing co-
localization of specific HGF receptor – c-Met and Bcl-xL in (A) bronchial and (B) alveolar epithelial 
cells. The pictures are representative of five IPF patients. Scale bars represent (A) 600 μm and 
(B) 100 μm. 
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4.1.5 Levels of HGF in BALFs and homogenates obtained from IPF 
and donor lungs 
 
As immunohistochemical results showed co-localization of Bcl-xL and c-Met receptor, 
further studies were performed to assess the amount of HGF in lung homogenate and in 
BALF. 
In a healthy lung HGF is produced in biologically inactive pro-form (~100 kDa) and 
stored as such within the extracellular matrix. It is then proteolytically activated 
specifically at sites of injury through several proteases. The active heterodimer consists 
of an α and a β subunit (69 kDa and 34 kDa respectively), and is recognized by all cells 
expressing the c-Met receptor. The anti-HGF antibody used for Western blot analysis 
recognized the cleaved (activated) and non-cleaved form of HGF. We observed, that in 
lung tissue of IPF subjects, the level of activated HGF is decreased when compared to 
donors. There was no statistically significant difference with regard to the expression of 
the non-cleaved form of HGF (Figure 4.5 A). 
As expected, non-cleaved HGF could not be detected in BALFs, as it is bound and 
stored in extracellular matrix. No significant changes in active HGF levels were 
observed in BALFs from IPF subjects in comparison to healthy donors (Figure 4.5 B). 
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Figure 4.5: HGF levels in lung homogenates and BALFs from IPF patients and organ donors. 
Western blot analysis of HGF expression in (A) lung homogenates and (B) BALFs from patients and 
organ donors. Beta-actin and albumin (coomassie stained membrane) were used as loading controls in 
case of lung homogenates and BALFs respectively. (A) IPFs n=18, donors n=10, (B) IPFs n=11, donors 
n=11. Relative density and original blots are representative of two technical replicates. *** p=<0,001. 
 
4.2 Role of Bcl-xL in HGF-mediated epithelial protection 
against oxidative stress 
 
HGF is a pleiotropic cytokine playing a role in a wide spectrum of biological processes. 
It has been shown to activate a number of anti-apoptotic signaling pathways, such as 
ERK/MAPK, PI3K/Akt or STAT3, thus improving survival of some cell types. To test 
whether HGF has a pro-survival effect on alveolar epithelial type II cells, we performed 
a set of in vitro experiments using the lung epithelial cell lines, MLE-12, MLE-15 and 
RLE-6TN. Since it has been believed that repetitive and chronic micro-injuries affecting 
lung epithelial cells play an important role in the development and conceivably the 
progression of pulmonary fibrosis, we used three pro-apoptotic stimuli that have been 
reported to play a role in IPF, namely the oxidative stress inducer, hydrogen peroxide, 
ER-stress inducer, thapsigargin (Chapter 4.3) and Fas ligand (Chapter 4.4). Moreover, 
having observed that the Bcl-xL levels are significantly changed in IPF, we further 
investigated the role of Bcl-xL in HGF-mediated cytoprotection against above 
mentioned cell death inducers. 
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4.2.1 Loss of Bcl-xL expression caused by oxidative stress-induced cell 
death 
 
Subconfluent cells were incubated for 24h with hydrogen peroxide in a concentration 
range of 200-2000 μM to provide a gradual increase of oxidative stress in the medium. 
Subsequently, LDH assay and Western blot analysis were performed to assess the level 
of cell death in each treatment variant. We observed, that increased apoptosis and total 
cell death level corresponded with decreased Bcl-xL expression in both, MLE-12 and 
MLE-15 cells (Figure 4.6). The highest Caspase 3 activation was detected at 
600-1000 μM hydrogen peroxide concentration.  
 
4.2.2 Pro-survival activity of HGF on cells treated with hydrogen 
peroxide 
 
Epithelial cells were grown until reaching about 80% of confluence and then incubated 
for 24h with 650 μM hydrogen peroxide simultaneously with or without HGF under 
serum-free conditions. To validate an optimal dose, mouse recombinant HGF was used 
at two different concentrations: 50 ng/ml and 100 ng/ml, based on the literature. Non-
treated cells served as a control. Consistent with the previous reports, we observed that 
HGF treatment significantly decreased Caspase 3 activation induced by H2O2 (Figure 
4.7 A, C). Moreover, anti-apoptotic effect of HGF correlated with significant increase 
of Bcl-xL expression in cell lysates when compared to cells treated only with hydrogen 
peroxide (Figure 4.7 B, D). Both concentrations of HGF used in the study, led to a very 
similar readout, thus we decided to use the 50 ng/ml dose in further studies with 
thapsigargin and Fas ligand. 
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Figure 4.6: Loss of Bcl-xL expression caused by hydrogen peroxide-induced cell death. 
Confluent MLE-12 (A, B, C) and MLE-15 (D, E, F) cells were treated with various H2O2 concentrations, 
for 24h. (A, D) Western blot analysis showed induction of apoptosis via activation of Caspase 3 with 
increasing H2O2 concentrations up to 1000 μM H2O2, (B, D) Constant increase of cell death detected by 
LDH activity assay after H2O2 treatment (C, F) The higher level of total cell death, the lower the 
expression of Bcl-xL protein in cell lysates. Values are represented as mean ± SEM, N=2. 
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Figure 4.7: Effect of HGF on epithelial cells during oxidative stress-induced apoptosis. 
Confluent MLE-12 (A, B) and MLE-15 (C, D) cells were treated with H2O2 and HGF simultaneously, for 
24h under serum-free conditions. (A, C) Western blot analysis shows activation of Caspase 3 upon 
hydrogen peroxide and/or HGF treatment, N=3 (B, D) Bcl-xL expression in cell lysates, N=3. * p=<0,05, 
** p=<0,01*** p=<0,001 versus control if not indicated otherwise. 
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4.2.3 Effect of c-Met inhibitor on HGF prosurvival activity 
 
To confirm cell-protective effect of HGF on lung epithelial cells and to validate its 
specific signaling through c-Met receptor, we performed in vitro experiments with the 
use of PHA-66572 on rat epithelial (RLE-6TN) cells. RLE-6TN cells were used due to 
the lack of a good antibody against mouse c-Met receptor and availability of the 
antibody recognizing rat protein. 
 
4.2.3.1 Dependency of c-Met inhibitor dose on phosphorylation of the 
receptor 
 
To investigate the applicability of PHA-66572 as an effective c-Met signaling inhibitor, 
we examined the effect of different concentrations of this inhibitor on receptor 
phosphorylation. RLE-6TN cells confluent to 50-60% were treated for 24h with PHA-
66572 at dose range of 0,02-2 μM. Subsequently, the cells were incubated with HGF 
(50 ng/ml) for 10 min and lysed for total protein isolation. Western blot analysis was 
performed to assess c-Met phosphorylation status at the tyrosine residues 
Y1234/Y1235, since they are involved in c-Met-mediated signal transduction (Figure 
4.8). We observed a decrease in c-Met phosphorylation already at the lowest PHA-
66572 concentration (0,02 μM), but complete inhibition of this process occurred at 
0,1 μM or higher dose. 
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Figure 4.8: Dependency of PHA-66572 dose on c-Met phosphorylation. 
RLE-6TN cells were treated with c-Met inhibitor at concentrations indicated on the graph. After 24h they 
were incubated with HGF of 50 ng/ml for 10 min. Western blot analysis shows phosphorylated c-Met 
(c-Met P) and total c-Met amount in cell lysate. 
Results 
51 
4.2.3.2 Increased Bcl-xL expression correlates with HGF-prosurvival 
activity 
 
Prior to H2O2 treatment, RLE-6TN cells were incubated for 24h with PHA-66572 under 
serum-free conditions. Subsequently, the cells were treated for 48h with HGF at the 
dose of 20 ng/ml (HGF added freshly every 24h) in medium with or without a c-Met 
inhibitor. Control cells were kept in serum-free medium for the same time. Afterwards, 
800 μM hydrogen peroxide in medium with or without inhibitor, but not containing 
HGF, was introduced to the cells. After 24h, LDH assay and Western blot analysis were 
performed to assess cell death level and Bcl-xL expression, respectively (Figure 4.9 A, 
B). We observed that treatment with HGF significantly reduced the level of cell death 
induced by hydrogen peroxide in RLE-6TN cells. As expected, incubation with PHA-
66527 effectively abolished HGF prosurvival activity. Inhibitor treatment itself did not 
affect cell viability (Figure 4.9 A). Western blot analysis showed decreased level of Bcl-
xL in control cells incubated with inhibitor in comparison to inhibitor-free conditions. 
The rescued cells treated with HGF showed higher Bcl-xL expression in comparison to 
the non-treated cells (Figure 4.9 B), again indicating that HGF-mediated pro-survival 
signaling may occur via altered Bcl-xL expression. Cell morphology was examined 
using phase contrast light microscopy. We observed that after H2O2 treatment with 
absence of HGF, the cells died extensively, while upon HGF treatment the condition of 
the cells was improved with markedly more cells attached to the plate (Figure 4.9 C). 
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Figure 4.9: Increased Bcl-xL expression correlates with HGF prosurvival activity on cells incubated 
treated with H2O2. 
RLE-6TN cells were treated with 800 μM hydrogen peroxide with or without HGF pre-treatment, in the 
presence or absence of c-Met inhibitor (as indicated on each graph). (A) LDH assay-assessed cell death 
quantification shows abolition of HGF prosurvival activity in the presence of PHA-66572, N=3, n=5 (B) 
Western blot analysis of Bcl-xL expression, N=3. ** p=<0,05, *** p=<p=0,001 versus control if not 
indicated otherwise. (C) Cell morphology. Pictures are taken under the same magnification (x20) and are 
representative of three independent experiments. 
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4.3 Role of Bcl-xL in HGF-mediated epithelial protection 
against ER-stress 
4.3.1 Loss of Bcl-xL expression caused by ER-stress-induced apoptosis 
 
To further investigate changes in Bcl-xL expression during pro-apoptotic stimulation, 
we treated confluent cells with another stress inducer - thapsigargin. Already at low 
concentrations, thapsigargin is a potent inhibitor of both endoplasmic and sarcoplasmic 
reticulum and Ca
2+
-ATPases in various cell types. It has been described to cause severe 
ER stress leading to cell death. 
MLE-12 and MLE-15 cells were incubated with increasing concentrations of 
thapsigargin for 24h and subsequently total protein was isolated and analyzed by 
Western blot. Both cell lines responded in the similar way to the treatment. We 
observed a strong induction of apoptosis via activation of Caspase 3 which correlated 
with decreased expression of Bcl-xL (Figure 4.10). 
 
4.3.2 Prosurvival activity of HGF on cells treated with thapsigargin 
 
MLE-12 and MLE-15 cells were treated for 24h with 5 nM thapsigargin and with or 
without HGF (50 ng/ml) in serum-free medium. HGF prosurvival effect was confirmed 
by Western blot analysis, which showed a decrease in Caspase 3 activation (Figure 4.11 
A) after HGF treatment under ER stress conditions. In agreement with what we 
observed for oxidative stress-induced cell death, we observed that MLE-12 cells that 
were rescued from apoptosis by HGF showed increased expression of Bcl-xL in 
comparison to cells incubated only with thapsigargin (Figure 4.11 B). Interestingly, we 
did not observe prosurvival HGF activity in MLE-15 cells upon the same experimental 
settings. We could detect a slight increase of Bcl-xL expression in HGF-treated cells, 
however it was not a statistically significant trend (Figure 4.11 C, D). 
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Figure 4.10: Loss of Bcl-xL expression during apoptosis induced by thapsigargin treatment. 
Confluent MLE-12 (A, B) and MLE-15 (C, D) cells were treated with different thapsigargin (Thg) 
concentrations, as indicated, for 24h. (A, C) Western blot analysis activation of Caspase 3 with increasing 
thapsigargin concentrations, N=2. (B, D) Bcl-xL protein level in cell lysates, N=2. 
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Figure 4.11: Prosurvival activity of HGF on cells treated with thapsigargin. 
Confluent MLE-12 (A, B) and MLE-15 (C, D) cells were treated with thapsigargin and HGF 
simultaneously, for 24h under serum-free conditions. (A, C) Western blot analysis shows Caspase 3 
cleavage upon thapsigargin and/or HGF treatment, N=3, (B, D) Bcl-xL expression in cell lysates, N=3. * 
p=<0,05, ** p=<0,01*** p=<0,001 versus control if not indicated otherwise. 
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4.3.3 Elevated level of Bcl-xL correlates with pro-survival activity of 
HGF 
 
RLE-6TN cells were incubated with 0,25 μM of the c-Met inhibitor PHA-66572 for 
24 h, prior to 48h long HGF (20 ng/ml) pre-treatment and subsequent 4 μM thapsigargin 
treatment for 24h. In agreement with previous results, we detected a reduction of cell 
death upon HGF treatment only in cells not incubated with c-Met inhibitor (Figure 4.12 
A). We did not observe the influence of c-Met inhibition on viability of the cells not 
stimulated with thapsigargin, however, the stimulated cells treated with PHA-66572 
seemed to be more sensitive to ER stress than control cells (Figure 4.12 A). Western 
blot analysis determined that increase of Bcl-xL expression was correlated with 
improved survival of epithelial cells and was only observed in HGF-treated cells with 
absence of inhibitor (Figure 4.12 B). The morphology of the RLE-6TN cells under 
control conditions remained unaltered after incubation with PHA-66572. Upon 
stimulation with thapsigargin cells in both variants (with or without inhibitor) died 
extensively and the majority detached from the culture plate. In contrast, HGF treatment 
resulted in markedly higher amount of surviving cells attached to Petri dish, which was 
not observed upon c-Met inhibitor pre-incubation (Figure 4.12 C).  
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Figure 4.12: Elevated level of Bcl-xL correlates with pro-survival activity of HGF. 
RLE-6TN cells were treated with thapsigargin with or without HGF pre-treatment, in the presence or 
absence of c-Met inhibitor (as indicated on each graph). (A) LDH assay shows cell death level under 
different cell culture conditions, N=3 (B) Western blot analysis of Bcl-xL expression in cell lysates, N=2, 
n=4. Values are represented as mean ±SEM. * p=<0,05, *** p=<0,001 versus control if not indicated 
otherwise. (C) Cell morphology. Pictures are taken under the same magnification (x20) and are 
representative of three independent experiments. 
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4.4 Expression level of Bcl-xL upon Fas ligand treatment 
4.4.1 No effect of FasL-induced apoptosis on Bcl-xL expression level 
 
Fas ligand belongs to tumor necrosis factor family. Its binding to cell death surface 
receptor Fas results in apoptotic cell death mediated by caspase activation. In order to 
induce apoptosis, subconfluent MLE-12 and MLE-15 cells were incubated different 
concentrations of FasL for 24h. We observed that in FasL dose of 50 ng/ml or higher 
effectively induced Caspase 3 cleavage (Figure 4.13 A, C). However, in contrast to our 
previous results, no changes in Bcl-xL expression were observed in response to 
apoptotic response mediated by FasL treatment (Figure 4.13 B, D). 
 
4.4.2 No protective effect of HGF on cells treated with FasL 
 
MLE-12 and MLE-15 cells were treated simultaneously with 50 ng/ml FasL in absence 
or presence of HGF at dose of 50 ng/ml, as indicated on the graphs. As previously, FasL 
treatment resulted in Caspase 3 activation with no concomitant alteration in Bcl-xL 
level. Under these conditions, HGF treatment did not result either in reduction of 
apoptosis or up-regulation of Bcl-xL expression (Figure 4.14). 
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Figure 4.13: No effect of FasL-induced apoptosis on Bcl-xL expression level. 
Confluent MLE-12 (A, B) and MLE-15 (C, D) cells were treated for 24 h with different concentrations of 
FasL, as indicated on the graphs. (A, C) Western blot analysis shows activation of Caspase 3 after FasL 
treatment, N=3, (B, D) Bcl-xL protein level in cell lysates, N=3. ** p=<0,01; *** p=<0,001 versus 
control. 
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Figure 4.14: Lack of HGF protective effect on cells treated with FasL. 
Confluent MLE-12 (A, B) and MLE-15 (C, D) cells were treated with FasL and HGF simultaneously for 
24 h under no serum conditions. (A, C) Western blot analysis shows activation of Caspase 3 after FasL 
and/or HGF treatment. (B, D) Bcl-xL expression under different treatment conditions. The pictures are 
representative of at least three independent experiments. *** p=<0,001 versus control. 
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4.5 siRNA knock-down of Bcl-xL 
 
Since HGF stimulation increased the expression of Bcl-xL under stress conditions, we 
used the siRNA targeted against Bcl-xL to further investigate its role in HGF-mediated 
epithelial cell protection.  
 
4.5.1 Analysis of siRNA-mediated knock-down of Bcl-xL 
 
Endogenous Bcl-xL expression was knocked-down with siGENOME SMARTpool 
siRNA oligonucleotides specific for murine Bcl-xL mRNA. Scrambled siRNA 
sequence was used as a specificity control. MLE-12 cells were transfected with 
DharmaFECT1 according to manufacturer’s instructions. In the initial experiments two 
concentrations (25 nM and 100 nM) of targeted/scrambled siRNA were used. For 
characterization of the level of gene knock-down real time analysis was performed 24h 
and 48h after transfection. We observed significant decrease of Bcl-xL expression 
already at 24h time point. The negative control siRNA caused no change in Bcl-xL 
mRNA expression (Figure 4.15 A). For validation of the knock-down system on the 
protein level, we used 25 nM siRNA and performed Western blot analysis after 24h, 
48h and 72h. (Figure 4.15 B). We demonstrated that Bcl-xL protein is markedly 
reduced already after 24h and its expression remains at low level up to 72h post-
transfection. 
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Figure 4.15: siRNA-mediated knock-down of endogenous Bcl-xL expression. 
Epithelial MLE-12 cells were transfected with 25 nM siRNA targeted against Bcl-xL and scrambled 
siRNA as negative control. (A) Real time analysis shows reduced Bcl-xL gene expression after 24 h and 
48 h after transfection, N=2. * p=<0,05, ** p=<0,01 *** p=<0,001. (B) Western blot demonstrates Bcl-
xL protein level at 24 . 48 h and 72 h post-transfection. The pictures are representative of at least two 
independent experiments.  
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4.5.2 Effect of Bcl-xL knock-down on HGF-mediated survival of cells 
treated with hydrogen peroxide 
 
To determine the role of Bcl-xL in HGF-mediated pro-survival effect on epithelial cells 
upon oxidative stress conditions, we treated the transfected cells with 650 μM hydrogen 
peroxide in the presence or absence of 24h long incubation with 20 ng/ml HGF. We 
noticed, that significant loss of Bcl-xL protein, caused increased sensitivity to injury of 
MLE-12 cells, demonstrated as a marked increase of cell death after treatment with 
H2O2 in comparison to cells transfected with scrambled siRNA. The cells with knock-
downed Bcl-xL showed higher cell death level also in control conditions, without any 
stress stimuli. Nonetheless, normal expression of Bcl-xL was not crucial for HGF-
mediated cell protection. HGF was able to rescue MLE-12 cells from cell death induced 
by hydrogen peroxide treatment in both cases, targeted and scrambled siRNA 
transfected variant (Figure 4.16 A). To validate if this effect is not a consequence of 
HGF-induced Bcl-xL re-expression, we performed Western blot analysis and found out 
that Bcl-xL level in transfected cells remains at a low level independently from HGF 
treatment (Figure 4.16 B).  
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Figure 4.16: Role of Bcl-xL in HGF-mediated epithelial cell protection. 
MLE-12 cells were transfected with anti-Bcl-xL siRNA or non-targeting siRNA, treated with 20 ng/ml 
HGF and then incubated with 650 μM hydrogen peroxide. (A) LDH cytotoxicity assay demonstrates cell 
death level under different cell culture conditions, N=5. *** p=<0,001 versus control if not indicated 
otherwise. (B) Western blot analysis shows Bcl-xL expression at the end of the experiment, N=3.  
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4.5.3 Effect of Bcl-xL knock-down on HGF prosurvival activity after 
thapsigargin treatment 
 
In order to examine the stress stimuli dependent specific reaction of epithelial cells to 
HGF, we conducted an analogous experiment, using the 2,5 nM thapsigargin as cell 
death inducer. In agreement with previous results, we found out that down-regulation of 
Bcl-xL affected cell survival even without stress stimuli, drastically increasing 
sensitivity of MLE-12 cells to ER-stress caused by thapsigargin treatment. However 
normal endogenous expression of Bcl-xL did not seem to be crucial for HGF-driven cell 
protection (Figure 4.17 A). HGF-driven pro-survival effect on MLE-12 cells was not 
dependent on up-regulation of Bcl-xL (Figure 4.17 B). 
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Figure 4.17: Role of Bcl-xL in HGF-mediated epithelial cell protection 
MLE-12 cells were transfected with anti-Bcl-xL siRNA or non-targeting siRNA, treated with 20 ng/ml 
HGF and then incubated with 2,5 μM thapsigargin. (A) LDH cytotoxicity assay demonstrates cell death 
level under different cell culture conditions, N=3. ** p=<0,01, *** p=<0,001 (B) Western blot analysis 
shows Bcl-xL expression at the end of the experiment, N=2. 
 
In conclusion, our in vitro data show that HGF has anti-apoptotic properties on alveolar 
epithelial cells under oxidative and ER stress conditions, which directly correlates with 
increased expression of Bcl-xL. Knock-down of Bcl-xL makes epithelial cells more 
sensitive to injury caused by hydrogen peroxide and thapsigargin. Bcl-xL is, however, 
not crucial for HGF cytoprotective activity. These data suggest that Bcl-xL is an 
important part of HGF/c-Met-mediated pro-survival response, but additional alternative 
molecular mechanisms are as well involved in the process. 
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5 Discussion 
5.1 Epithelial apoptosis in IPF 
5.1.1 What is the role of epithelial apoptosis in IPF? 
 
IPF is a chronic interstitial pulmonary disease of unknown etiology. It is characterized 
by the formation of scar tissue within the lung, and results in a progressive decline in 
exercise capacity, restriction on lung function and ultimately a fatal outcome (King et 
al., 2011). The pathogenesis of IPF has been the subject of extensive investigation. 
According to a current hypothesis, repetitive injury to the alveolar epithelium is 
followed by impaired wound healing and this represents the early driving force for the 
development of the disease (Zoz et al., 2011). Persistent injury and excessive apoptosis 
of AEC seem to lead to an aberrant epithelial activation with synthesis of a variety of 
profibrotic factors (e.g. TGF-β, PDGF), fibroblast/myofibroblast expansion, deregulated 
remodeling and finally irreversible restructuring of the lung parenchyma (Selman et al., 
2002). 
Apoptosis has been clearly recognized in the alveolar epithelium in human tissue 
samples of patients with IPF. Such analysis of lung sections revealed DNA strand 
breaks as well as positive immunohistochemical signals for p53 and p21 in bronchial 
and alveolar epithelial cells in mild and moderate fibrotic lesions, with the most 
prominent staining in areas with so called “hyperplastic” type II cells (Kuwano et al., 
1996). By employing electron microscopy it has been confirmed that dying 
pneumocytes are directly adjacent to fibroblastic foci, however, those cells displayed 
morphological characteristics of both apoptosis and necrosis (Uhal et al., 1998). 
Additionally, in a later study, it has been demonstrated that apoptotic type II cells can 
also be found in regions with still regular appearing architecture, suggesting they may 
be involved in early events during development of the disease (Barbas-Filho et al., 
2001). In principle, alveolar epithelial type II cells play a key role in re-epithalization of 
intact alveoli. They have a high regenerative potential and are capable of abundant self-
renewal and regeneration. AECII are also described to be progenitor cells with potential 
to differentiate into AECI following injury (Barkauskas et al., 2013, Fehrenbach, 2001). 
However, in IPF, these processes appear to be disturbed. Persistent damage, initial or 
secondary, with subsequent excessive cell death of epithelium is increasingly accepted 
as the key event in of IPF. In support of this theory, a targeted injury of AECIIs has 
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been shown to induce pulmonary fibrosis in vivo. In the study of Sisson et al., 
transgenic mice expressing the human diphtheria toxin receptor (DTR) under the SP-C 
promoter were exposed to diphtheria toxin (DT) to specifically aim the type II epithelial 
cells. Histological evaluation revealed that administration of DT resulted in diffuse 
collagen deposition with patchy areas of more confluent scarring associated with 
significant increase in hydroxyproline content in the lungs of DTR-expressing animals 
in comparison to controls (Sisson et al., 2010). Furthermore, the mutations in genes 
encoding surfactant protein C (SFTPC) and A (SFTPA) have been found in patients 
with familial forms of IPF (FPF). Clinical symptoms of FPF, treatment outcomes and 
histological findings (UIP) are indistinguishable from sporadic cases of IPF, except 
from the younger age at diagnosis. It has been suggested that up to 20% of cases might 
be familial (Kropski et al., 2013). Until now, several different mutations of SFTPC and 
SFTPA have been detected in FPF patients. The common feature of all identified 
mutations is that they involve amino acids in highly conserved regions and are believed 
to disrupt a C-terminal domain proven to be crucial for the proper folding and 
processing of the surfactant proteins (Thomas et al., 2002, van Moorsel et al., 2010, 
Wang at al., 2009b). In vitro studies have demonstrated that the expression of mutant 
SFTPC in human or murine lung epithelial cell lines promoted up-regulation of multiple 
ER-stress species (e.g. Bip, Xbp-1) as well as activation of Caspase 3 (Mulugeta et al., 
2005, Thomas et al., 2002). Additionally, disruption of a C-terminal domain of SFTPA2 
in A549 cells led to accumulation of misfolded SP-A2 in ER and activation of the UPR 
(Wang et al., 2009b). Since SFTPC and SFTPA are expressed exclusively by AECII in 
the lungs, these findings support a model according to which mutations observed in FPF 
predispose to fibrosis via induction of type II cell death and provide evidence linking 
the type II cell injury to the development of lung fibrosis. 
According to published studies, a number of factors contribute to the cytotoxic effect on 
lung epithelium, including DNA damage, oxidative and ER stress response pathways. 
Moreover, multiple different pathways are activated in fibrosis such as chemokines, 
pro-coagulant molecules and growth factors, that modify production of pro-apoptotic 
mediators (FasL, TNF-α, angiotensin peptides) (Günther et al., 2012, Hecker et al., 
2011). In our study we focused on three major pro-apoptotic stimuli affecting type II 
cells in fibrotic lung: oxidative stress, ER stress and FasL. Knowing that HGF has anti-
fibrotic properties in experimental models of lung fibrosis, we were interested if 
mediating survival of alveolar epithelial cells exposed to damaging factors may be one 
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of the mechanism via which HGF promotes resolution of fibrotic remodeling. At the 
centre of our focus was the role of Bcl-xL in this context. 
 
 
5.1.2 Reactive oxygen species production in fibrotic lung 
 
Oxidative stress has been described to contribute to the pathophysiology of interstitial 
lung diseases including IPF, fibrosing alveolitis associated with systemic sclerosis and 
sarcoidosis (Kliment et al., 2010). It is mainly referred to as the imbalance of oxidant 
production and antioxidant defenses, where oxidants dominate and lead to tissue 
damage. The main source of reactive oxygen species in IPF lung are alveolar 
macrophages, neutrophils and eosinophils. These cells release metabolic oxygen 
products including hydrogen peroxide and superoxide anions into the local 
microenvironment, and thereby affect adjacent cells (Kliment et al., 2010). Permanent 
oxidative stress may lead to increased susceptibility to injury and apoptosis of lung 
epithelium either directly or by activating redox-sensitive pathways, such as 
Ras/Raf/MAPK or PI3K/Akt that are implicated in TGF-β -induced EMT. Furthermore, 
ROS have been shown to directly activate latent TGF-β as well as induce TGF-β gene 
expression, thus positively affecting fibroblast proliferation and differentiation into 
myofibroblasts or enhanced production of ECM proteins (Liu et al., 2010). Changes in 
oxidant-antioxidant balance can be quantified in biological systems by measuring the 
levels of ROS themselves (e.g. hydrogen peroxide) or by measuring the end products of 
oxidation if cell components, such as carbonylated proteins or 8-isoprostane and 
exhaled ethane (as markers of lipid peroxidation). Elevated concentrations of all 
mentioned ROS or ROS by-products have been reported in IPF and have been found 
negatively correlated with pulmonary function (Bargagli et al., 2007, Kanoh et al., 
2005, Montuschi et al., 1998, Psathakis et al., 2006). Furthermore, IPF fibroblasts have 
been shown to generate hydrogen peroxide in response to TGF-β1 and to induce cell 
death of co-cultured small airway epithelial cells (Waghray et al., 2005).  
Concurrently to elevated levels of ROS, a marked reduction of anti-oxidant defense has 
been described in IPF. The antioxidant protection is mainly provided by intracellular 
glutathione (GSH), that functions via several enzymes catalyzing hydrogen peroxide 
and lipid peroxide reduction as well as retaining protein cysteine residues in their 
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reduced form (Liu and Pravia, 2010). In several studies deficiency of GSH in the lower 
respiratory tract of IPF patients has been described, including decreased levels of 
glutathione in BALFs, sputum and plasma of IPF subjects when compared to controls 
(Beeh et al., 2002, Cantin et al., 1989). Moreover, a marked reduction of major 
antioxidant enzyme of the extracellular matrix, superoxide dismutase was found in IPF 
lung tissues. Additionally, the immunohistological analysis of IPF/UIP sections 
revealed absence of EC-SOD in fibrotic areas and fibroblast foci (Kinnula et al., 2006). 
In the current study, we used hydrogen peroxide to induce oxidative stress conditions in 
vitro. We observed that simultanous treatment of mouse epithelial cell lines MLE-12 
and MLE-15 with HGF and H2O2 for 24h resulted in improved survival of the cells 
when compared to control conditions without HGF, and this appeared to be associated 
with increased expression of Bcl-xL (Figure 4.7). We confirmed this result using rat 
RLE-6TN cells, where we detected a reduced total cell death after HGF treatment. This 
effect was abolished by using a c-Met inhibitor (Figure 4.9). Similar results to ours were 
obtained in renal tubular epithelial cells. Treatment with HGF 48h prior to induction of 
apoptosis caused by oxidative stress resulted in improved cell survival. Both, Bad 
phosphorylation and increased Bcl-xL expression were the necessary events for that 
effect to occur. Simultaneous HGF and oxidative stress exposure failed to reduce 
apoptosis level in tubular cells, which was due to the fact that only phosphorylation of 
Bad took place, without up-regulation of Bcl-xL, which was assessed to be a critical 
event (Zhang et al., 2008). Knowing that Bcl-xL is involved in the HGF-driven 
cytoprotective actions against hydrogen peroxide on alveolar epithelial cells, we further 
investigated its impact on this process. In this purpose we transfected the cells with 
siRNA to specifically knock down Bcl-xL and subsequently exposed it to HGF and 
oxidative stress conditions. As expected, we observed that loss of Bcl-xL made cells 
more sensitized to injury, however HGF treatment remained profitable and resulted in 
improved cell survival despite the low level of Bcl-xL (Figure 4.16). Taken together, 
these findings indicate that up-regulation of Bcl-xL expression is one of the several 
mechanisms through which HGF/c-Met mediate prosurvival activity on the lung 
epithelium. However, Bcl-xL-based signaling seems not to be crucial for maintaining 
the HGF anti-apoptotic activity. A limitation in our study was that we used an siRNA-
based approach, which did not result in a 100% knock-down of Bcl-xL. Hence, the 
dependency of HGF-elicited cytoprotective effect may have been much more evident if 
we would have been able to completely silence Bcl-xL in our experimental approach. In 
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line with this view, Takehara et al. observed that mice with a complete Bcl-xL gene 
knock-out in hepatic epithelial cells showed consistent apoptosis of these cells, and 
spontaneously developed liver fibrosis after 6 months (Takehara et al., 2004). Thus, 
prolonged and complete Bcl-xL deficiency, potentially resembling a more chronic 
process, may be necessary to assess its role in vivo in the context of fibrotic remodeling. 
This has been also indicated by the study performed by Staversky et al. They 
investigated the effect of disruption of Bcl-xL in AECII in context of lung development. 
Interestingly, they observed that short term knock-out of Bcl-xL in those cells did not 
affect pulmonary function or epithelial marker expression, but resulted in a shift of the 
lung toward a pro-apoptotic state and an increased sensitivity of the respiratory 
epithelium to oxygen-induced cytotoxicity (Staversky et al., 2010).  
 
 
5.1.3 ER stress response in fibrosing lung 
 
The endoplasmic reticulum contains chaperones that promote correct folding of a wide 
range of protein components in the cell. It has been well established that under normal 
conditions the activation of the ER stress response is a cytoprotective mechanism 
aiming to help misfolded proteins to re-fold and restore homeostasis. The process 
occurs through activation of several signaling pathways which affect synthesis of 
chaperones and proteasomal compounds responsible for degradation of irreparable 
products, lipid production or anti-ROS signaling. In principle, it is a fundamental 
process promoting cell survival. However, in case of overwhelming or prolonged stress 
conditions, a cell is driven into apoptosis via activation of CHOP and ATF-4 (Günther 
et al., 2012). Our group has previously shown that severe ER stress response triggers 
apoptosis of type II pneumocytes in IPF and may be implicated in development of the 
disease. By means of immunohistochemistry we were able to localize ER stress 
response elements, e.g. ATF-6, ATF-4 and CHOP, in AECII adjacent to fibroblast foci 
and in the regions of dense fibrosis of IPF patients, to a lower extent in still healthy 
appearing areas of IPF lung, but not in donor lungs. Moreover, the expression of ER 
stress markers co-localized with cleaved Caspase 3 and TUNEL signaling in those cells. 
We also detected enhanced ER stress response pathway activation in lung tissues 
obtained from IPF subjects (Günther et al., 2012, Korfei et al., 2008). Moreover, the 
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prominent role of ER stress in the pathogenesis of pulmonary fibrosis has been recently 
implied by Lawson et al. in an in vivo study in mice overexpressing the mutant form of 
protein surfactant C. In these animals, a constant ER stress response was associated with 
increased apoptosis of alveolar epithelial type II cells and enhanced fibrotic remodeling 
in the lungs after bleomycin application in comparison to control mice (Lawson et al., 
2011).  
Having determined that exaggerated activation of ER stress pathways may be one of the 
key mediators of AECII excessive apoptosis, we next focused on the impact of HGF on 
the survival of alveolar epithelial cells exposed to ER-stress inducing agent and the role 
of Bcl-xL in this context. To induce ER stress conditions we used thapsigargin, a potent 
inhibitor of ER and SR trafficking. As previously described for oxidative stress 
conditions, we observed similar effect and an interdependency between HGF and Bcl-
xL on epithelial cells exposed to thapsigargin: HGF treatment improved survival of 
MLE-12 and RLE-6TN cells, which occurred through up-regulation of Bcl-xL level. 
This effect was abrogated in cells incubated with c-Met inhibitor (Figure 4.11 and 4.12). 
Knock-down, although incomplete, of Bcl-xL made MLE-12 cells markedly more 
sensitive to injury caused by thapsigargin, and again did not entirely suppress HGF 
cytoprotective activity (Figure 4.16).  
Collectively, these data indicate that up-regulation of Bcl-xL expression is one of the 
potential mediators involved in HGF-promoted epithelial protection against oxidative as 
well as ER stress. The impairment of HGF production and activation observed in IPF 
may be one of the reasons for deregulation of Bcl-xL levels in lung epithelium 
potentially leading to insufficient Bcl-xL synthesis, thus favouring the development and 
progression of lung fibrosis. 
 
 
5.1.4 Activation of death receptor pathway in IPF 
 
The extrinsic pathway of apoptosis is activated by extracellular signals that result in the 
binding of specific ligands to the transmembrane receptors belonging to the tumor 
necrosis factor (TNF) receptor superfamily. Death receptor ligation triggers recruitment 
of the precursor form of Caspase 8 to a death-inducing complex through the adaptor 
protein FADD, which leads to subsequent Caspase 3 activation and execution of 
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apoptotic cell death (Kuwano et al., 2005). Best described mediators of that pathway are 
TNF-α and Fas ligand (FasL). Fas receptor (FasR)/FasL system is considered to be the 
most efficient start point of the extrinsic pathway, and therefore to play a crucial role in 
the regulation of cell survival (Kopiński, et al., 2011). It has been reported that IPF 
lungs exhibit increased FasL expression, especially in bronchial and alveolar epithelial 
cells when compared to healthy subjects. The enhanced levels of soluble FasL and FasL 
encoding mRNA has been also found in BALFs as well as in serum of IPF subjects 
(Kopiński et al., 2011, Kuwano et al., 1999, Kuwano et al., 2002). Although the exact 
role of FasR/FasL signaling in the development of ILDs has not been extensively 
explored, it has been accepted to be a significant factor contributing to the pathogenesis 
of IPF (Kuwano et al., 2002). In the present study, we showed that FasL-mediated 
induction of apoptosis in MLE-12 and MLE-15 cells did not influence the Bcl-xL 
expression. Interestingly, even upon strong activation of Caspase 3, the cellular level of 
Bcl-xL remained unaltered (Figure 4.13). In line with these results, we did not observe 
any effect of HGF treatment on cellular survival (Figure 4.14). Our findings can be 
related to the study performed by Hagimoto et al.. They observed that TGF-β-induced 
activation of Caspase 3 cleavage in bronchiolar epithelial cells also did not result in the 
down-regulation of Bcl-xL expression. Moreover, they demonstrated that TGF-β1 acts 
as an enhancer of Fas-mediated apoptosis in small airway epithelial cells (Hagimoto et 
al., 2002). Thus potentially, HGF which has an indirect effect on AECII survival, may 
still function through alternative mechanisms independent from Bcl-xL, for example by 
counteracting TGF-β signaling.  
 
 
5.2 Epithelial protection, anti-apoptotic pathways in IPF 
5.2.1 Impairment of the HGF system in IPF 
 
HGF is a cytokine with pleiotropic functions during wound healing and repair. It’s 
synthesized as a inactive precursor and proteolytically activated by several proteases 
specifically at sites of injury. Elevated levels of circulating HGF are observed as a 
response to a variety of insults. HGF can act as an endocrine, a paracrine or an autocrine 
factor for cells expressing the c-Met receptor, e.g. alveolar epithelial cells (Mason, 
2002). However, the exact role of HGF during development and progression of IPF is 
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yet not fully understood. A few studies have reported that a total amount of HGF is 
increased in serum as well as in BALF obtained from IPF patients as compared to 
control subjects (Crestani et al., 2002, Hojo et al., 1997, Yamanouchi et al., 1998). 
Within this study we performed Western blot analysis of HGF expression in lung tissue 
homogenates and BALFs. We observed, that in lung tissue of IPF subjects, the level of 
activated HGF is decreased when compared to donors. There was no statistically 
significant difference with regard to the expression of the non-cleaved form of HGF 
(Figure 4.5 A). Analysis of BALFs showed no significant changes in active HGF levels 
observed in BALFs from IPFs in comparison to control subjects. The precursor form of 
HGF could not be detected, since it is normally stored in ECM or circulates in plasma. 
We speculate that, under pathological conditions in IPF, the up-regulation of pro-HGF 
does either not result in proper activation or insufficient downstream signaling in order 
to help the alveolar epithelium to better withstand endogenous as well as exogenous 
stress and to limit the magnitude of epithelial apoptosis and lung fibrosis. In this regard, 
application of exogenous HGF has been proven anti-fibrotic in several experimental 
models of various organ fibrosis including the lung (reviewed in Table 1). In vivo 
electroporation-mediated HGF gene expression in bleomycin treated mice resulted in 
reduction of pulmonary fibrosis, as assessed by Ashcroft’s numerical score and 
hydroxyproline content of the lung. Moreover, HGF transfer to bleomycin-challenged 
lung markedly improved survival of animals and significantly reduced the apoptotic cell 
index compared with animals transfected with control vector (Umeda et al., 2004). 
Similarly, intratracheal application of recombinant HGF protein attenuated collagen 
deposition and led to reduction of fibrotic changes in the lung induced by bleomycin. In 
addition, exogenous administration of HGF has been shown to have other beneficial 
effects, such as induced pulmonary epithelial cell proliferation, stimulation of the 
fibrinolytic capacity of the lung and cell migration (Dohi et al., 2000). These findings 
show that HGF is an essential factor for organ repair and protection. On the other hand, 
it is important to consider that long term use of HGF may stimulate extensive 
proliferation, survival or motility that in turn may lead to cancer. HGF/c-Met signaling 
has been shown to contribute to oncogenesis and tumor progression as well as promote 
cellular invasiveness strongly linked to tumor metastasis (Mizuno and Nakamura, 
2013). Thus, before application, a proper time and dose of HGF have to be established. 
In line with observations in animal models of pulmonary fibrosis, fibroblasts from IPF 
lungs have been shown to reveal a low capacity to activate pro-HGF due to decreased 
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production of HGF activator as well as increased synthesis of the HGFA inhibitors 
HAI-1 and HAI-2 (Marchand-Adam et al., 2006). In accordance with such observation, 
we detected a decreased expression of activated HGF in IPF versus donors lungs, in 
absence of a significant difference in non-cleaved HGF (Figure 4.5 A). Another factor 
limiting HGF-mediated signaling in IPF may be a posttranslational modification of the 
serine residue present in the juxtamembrane domain of c-Met receptor. c-Met is a 
tyrosine kinase, thus signal transduction occurs via phosphorylation of tyrosine residues 
localized in the receptor’s catalytic domain and multifunctional docking site. 
Phosphorylation of serine at position 985 of c-Met has been described to be of critical 
importance for limiting cellular responsiveness to HGF depending on the extracellular 
environment. Ser 985 phosphorylation is regulated by reverse activities of protein 
kinase C and protein phosphatase 2A (PP2A) and results in an inhibition of biological 
responses to HGF (Gandino et al., 1994, Hashigasako et al., 2004). Once organ tissue 
undergoes injury, Ser 985 site becomes dephosphorylated via recruitment of PP2A, 
which leads to regenerative action triggered by HGF. Since tissue damage leads to an 
increase of plasma HGF, hereby to systemic exposure to the growth factor, this 
mechanisms allows intact organs to escape c-Met activation via Ser 985 
phosphorylation (Nakamura and Mizuno, 2010). The status of c-Met Ser 985 
phosphorylation in IPF lungs has not been investigated up to date. However, it has been 
reported that fibroblasts from IPF patients have a lower capacity to induce PP2A 
activity in vitro, as well as to exhibit a reduced PP2A expression in comparison to 
control fibroblasts (Xia et al., 2012). Studies performed on scleroderma fibroblasts 
suggest that decreased PP2A levels in fibrotic environment may be a result of 
constitutively activated TGF-β signaling (Samuel et al., 2010). TGF-β is a major 
profibrotic molecule involved in initiation and progression of pulmonary fibrosis. It has 
been described to be greatly increased in IPF lungs, especially in alveolar epithelium, 
which constitutes the main site of its synthesis (Kapanci et al., 1995). TGF-β can induce 
the recruitment of inflammatory cells, the proliferation and myofibroblastic 
differentiation of fibroblasts as well as epithelial-to-mesenchymal transition 
(Leppäranta et al., 2012). It has been shown that TGF-β1 suppresses HGF secretion and 
conversion into its biologically active form in IPF fibroblasts (Marchand-Adam et al., 
2006, Matsumoto et al., 1992). Hence, excessive activation of TGF-β could contribute 
to a further impairment of the HGF system. 
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5.2.2 Role of Bcl-2 family in IPF 
 
Bcl-2 family comprises proteins involved in mitochondrial control of apoptosis. 
Functionally, they can be classified into three groups: anti-apoptotic (e.g Bcl-2, Bcl-xL), 
pro-apoptotic (e.g. Bax, Bak) and regulatory BH-3-only proteins that posses the ability 
to bind to anti- as well as pro-apoptotic members of the family (e.g. Bid) and thus 
function as initial sensors that integrate and transmit apoptotic signal to other Bcl-2 
family proteins (Adams and Cory, 1998, Chipuk et al., 2010). According to existing 
evidence, several proteins belonging to the Bcl-2 family have been implicated to play a 
role in the pathogenesis of various organ fibrosis, including lung, kidney, liver and heart 
(Budinger et al., 2006, Nakamura et al., 2000, Takehara et al., 2004, Zhang et al., 2001, 
Zhang et al., 2008). The group of Budinger et al. reported that the pro-apoptotic Bcl-2 
family member Bid is required for the development of pulmonary fibrosis induced by 
bleomycin instillation in mice. Alveolar epithelial cells isolated from Bid-null mice 
were resistant to TGF- β1-induced cell death, whereas TGF-β1 levels in BALFs as well 
as TGF-β1-inuced fibroblast proliferation were not affected by loss of Bid. These 
findings suggest that Bid may play a crucial role in epithelial protection during 
development of pulmonary fibrosis (Budinger et al., 2006). 
In line with this view, IPF lungs exhibit altered expression of Bcl-2 family members, as 
shown by Plataki et al. They have observed that hyperplastic AECII of IPF patients 
show increased expression of pro-apoptotic Bax and down-regulation of anti-apoptotic 
Bcl-2 in comparison to type II cells of control subjects (Plataki et al., 2005). Since it has 
not been investigated before, now we analyzed the expression pattern and total amount 
of Bcl-xL in IPF lungs. The immunohistochemical analysis of lung sections 
demonstrated presence of Bcl-xL in bronchial and alveolar epithelial cells in both IPF 
and control subjects (Figure 4.2). Interestingly, we noticed the most prominent 
expression in hyperplastic type II cells found in the regions of dense fibrosis. We could 
also observe strong signal in bronchial epithelial cells of fibrotic lung, whereas healthy 
donor sections revealed only weak staining, especially present in AECII. These findings 
were confirmed by lung homogenate analysis, which showed significant increase of 
total amount of Bcl-xL in IPF tissues versus control (Figure 4.1 A). Bcl-xL was below 
the detection level in the BALFs obtained either from healthy or IPF subjects (Figure 
4.1 B).  
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Taking into consideration that we found elevated level of pro-survival Bcl-xL especially 
in the hyperplastic type II cells that have been shown previously to undergo DNA 
fragmentation and express pro-apoptotic markers including those that belong to Bcl-2 
family, we hypothesize that up-regulation of Bcl-xL in the fibrotic lung may be a part of 
a compensatory mechanism, activated in attempt to rescue injured pneumocytes (Plataki 
et al., 2005, Uhal et al., 1998). A similar finding was obtained by Kitamura et al. in the 
context of Alzheimer’s disease (AD), a neurodegenerative disorder associated with 
widespread neuronal death. Examination of temporal cortex showed elevated level of 
the pro-apoptotic Bcl-2 family members Bad and Bak coinciding with Bcl-xL up-
regulation in AD patients in comparison to controls (Kitamura et al., 1998). Moreover, 
the exposure of cultured rat neurons to subtoxic dose of β-amyloid peptides, inducer of 
oxidative stress and cell death mediator, resulted in an increased level of Bcl-xL with no 
significant induction of apoptosis, whereas stable overexpression of Bcl-xL was still 
able to promote neuronal protection against cytotoxic concentrations of β-amyloids and 
apoptosis (Luetjens et al., 2001). These data suggest, that increased Bcl-xL expression 
may be an important event in response to stress stimuli such as oxidative stress. 
However the fact that ongoing and permanent apoptosis of neuronal cells, in case of 
AD, or alveolar epithelial cells in IPF, possibly leads to a constant progression of 
pathological condition, verifies that the system is insufficient or impaired.  
Furthermore, we studied the expression pattern of Bcl-xL in IPF sections presenting 
normal lung structure with adjacent areas of fibrotic remodeling (Figure 4.3). Spatial 
heterogeneity is a characteristic feature of UIP/IPF. Since the disease constantly 
progresses with time, we believe that the regions with still unaltered parenchymal 
architecture potentially represent an early stage of fibrosis. In agreement with previous 
results, hyperplastic AECII revealed strong immunohistological staining for Bcl-xL, 
whereas type II cells present in the still regular appearing regions of IPF lung sections 
appeared to have much weaker Bcl-xL expression, resembling that observed for donor 
lung. This indicates that Bcl-xL may be a part of mechanism involved in suppressing 
the progression of already existing pro-fibrotic changes rather than in the initial 
development of this pathological condition. 
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5.3 Conclusions and future directions 
 
Idiopathic pulmonary fibrosis is a chronic disease of unknown etiology, characterized 
by the formation of scar tissue within the lung (King et al., 2011). In agreement with a 
current concept, occurrence of a sequential injury and excessive apoptosis of alveolar 
epithelial cells followed by impaired wound healing process represents the leading 
cause for the development of IPF (Selman et al., 2002, Zoz et al., 2011). Apoptosis has 
been clearly recognized in the alveolar epithelium in human tissue samples with IPF, 
especially in the areas with adjacent to fibroblast foci with so called “hyperplastic” type 
II cells (Kuwano et al., 1996). In familial cases of IPF, observed mutations in the genes 
encoding surfactant protein C and A, have been suggested to predispose to pulmonary 
fibrosis via induction of enhanced ER stress and UPR response that leads to reduction 
of AECII viability (Kropski et al., 2013). For this reason the present study focused on 
alveolar epithelial cells. Since HGF has been proven to posses anti-fibrotic properties in 
experimental models of pulmonary fibrosis and, at the same time, to be impaired in 
human IPF, we investigated if HGF-promoted resolution of fibrotic changes may be due 
to its protective activity on type II cells driven into apoptosis by using three major 
stimuli present in fibrotic lung: oxidative stress, ER stress and FasL-triggered apoptosis. 
At the centre of our focus was the role of anti-apoptotic protein Bcl-xL in the 
HGF/c-Met-mediated cytoprotection. Our in vitro studies on mouse and rat lung 
epithelial cell lines revealed that up-regulation of Bcl-xL expression is one of the 
mechanisms involved in HGF/c-Met-mediated cytoprotective activity on epithelial cells 
in conditions of oxidative and ER stress. It would be beneficial to investigate the role of 
HGF in this regard on the primary alveolar epithelial cells isolated from bleomycin 
treated mice, or at best, from human fibrotic lung. Since it is hypothesized that acquired 
or genetic dysfunction of AECII may be the underlying cause for increased sensitivity 
of epithelium to injury and may lead to aberrant wound healing, employing primary 
type II cells from fibrotic lung would be of advantage, as they may respond differently 
than cells from healthy organ. 
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Fig 5.1: Schematic representation for proposed role of Bcl-xL and HGF in idiopathic pulmonary 
fibrosis.  
 
Furthermore, we have found that activation of extrinsic apoptotic pathway via FasL 
treatment did not alter Bcl-xL expression and no anti-apoptotic effect of HGF could be 
observed in this case, suggesting that HGF is able to promote anti-apoptotic effect on 
epithelial cells only in response to an activation of the intrinsic pathway. It is possible 
that, HGF would be capable of mediating pro-survival signaling also when extrinsic 
pathway is triggered in vivo, however only in a indirect manner, for example through 
counteracting TGF-β signaling. Thus, in vivo studies using bleomycin model could 
provide additional information about a role of Bcl-xL and its dependency on HGF 
system in development and progression of pulmonary fibrosis.  
Interestingly, we observed that IPF lungs exhibit a significant increase of total amount 
of Bcl-xL in comparison to donor lung, with the most prominent expression in 
hyperplastic type II cells found in the regions of dense fibrosis. Taking into account that 
an increase of Bcl-xL synthesis mediated by HGF treatment had a beneficial effect on 
injured epithelial cells as well as the observation of Plataki et al. group that hyperplastic 
type II cells show a decreased expression of another pro-apoptotic Bcl-2 family 
member, we speculate that Bcl-xL may be a part of compensatory mechanism, activated 
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in attempt to rescue injured pneumocytes (Plataki et al., 2005). However the fact that 
HGF production and activation is impaired in IPF may be a potential explanation for 
insufficient epithelial protection favoring the progression of lung fibrosis (Figure 5.1). 
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6 Appendix 
 
6.1 List of primary antibodies 
 
Antibody against Source Dilution Application Company 
Bcl-xL Rabbit 1:4000 WB Abcam 
Bcl-xL Rabbit 1:50 IHC Abcam 
Beta-Actin Rabbit 1:10000 WB Abcam 
Beta-Actin Mouse 1:10000 WB Abcam 
cc-10 Rat 1:75 IHC R&D Systems 
Cleaved Caspase 3 Rabbit 1:1000 WB Cell Signaling 
c-Met Rabbit 1:100 IHC  Abcam 
c-Met Rabbit 1:1000 WB Abcam 
c-Met Phoshpo Rabbit 1:1000 WB Cell Signaling 
Cytokeratin 5 Rabbit 1:200 IHC Abcam 
HGF Rabbit 1:400 WB Santa Cruz 
Pro-SPC Rabbit 1:750 IHC Millipore 
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